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5ABBREVIATIONS
AC Adenylate cyclase
4-AP 4-aminopyridine
ATP Adenosine triphosphate
β2-agonist β2-adrenergic agonist (β2-adrenoreceptor agonist)
[Ca2+]i Intracellular calcium concentration
ChTX Charybdotoxin
cNOS (type III NOS) Constitutive nitric oxide synthase
cyclic AMP Cyclic adenosine 3’,5’-monophosphate
cyclic GMP Cyclic guanosine 3’,5’-monophosphate
EC50 or EC30  Concentration of drug producing 50% or 30% of the
maximum relaxation, respectively
Gi Inhibitory G protein (a subgroup of G proteins)
GEA 3268 1,2,3,4-oxatriazolium, 3-(3-chloro-2-methylphenyl)-
5-[[(4-methoxyphenyl)sulfonyl]amino]-, hydroxide inner 
salt
GEA 5145 1,2,3,4-oxatriazolium, 3-(3-chloro-2-methylphenyl)-
5-[(methylsulfonyl)amino]-, hydroxide inner salt
Gs Stimulatory G (a subgroup of G proteins)
GS Guanylate cyclase
GSNO S-nitrosoglutathione
H2O2 Hydrogen peroxide
IBMX 3-isobutyl-1-methylxanthine
IbTX Iberiotoxin
IKCa Intermediate conductance calcium-sensitive K+ channels
iNOS (type II NOS) Inducible nitric oxide synthase
IP3 Inositol-(1,4,5)-triphosphate
KATP ATP-sensitive K+ channel
KCa Calcium-sensitive K+ channel (BK, large conductance)
Ke Extracellular K+
KIR Inward rectifier K+ channels
KV Voltage-dependent (= delayed rectifier) K+ channels
M2 Muscarinic 2-receptor
M3 Muscarinic 3-receptor
Na+-K+-ATPase Na+-K+-adenosine triphosphatase
NADPH Nicotinamide adenine dinucleotide phosphate
NO Nitric oxide
NO2- Nitrite
NO3- Nitrate
NOx NO2- + NO3-
NOS Nitric oxide synthase
PIP2 Phosphatidylinositol-(4,5)-bisphosphate
PK Protein kinase
PKA Protein kinase A (cyclic AMP-dependent protein kinase)
PKG Protein kinase G (cyclic GMP-dependent protein kinase)
6Po Open probability of a channel
O2- Superoxide
ODQ 1H-[1,2,4]oxadiazolo[4,3-a]quinozalin-1-one
ONOO- Peroxynitrite
RSNO S-nitrosothiols
S.E.M. Standard error of the mean
SIN-1 3-morpholino-sydnonimine
SKCa Small conductance calcium-sensitive K+ channels
SNAP S-nitroso-N-acetylpenicillamine
SNP Sodium nitroprusside
TEA Tetraethylammonium
Vm Membrane potential
VOC Voltage-operated calcium channels
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ABSTRACT
There is an increase in nitric oxide (NO) levels in the air exhaled by asthmatic patients. NO has
been shown to dilate airways in vivo both in animals and in humans. NO donors have a
bronchodilatory action in vitro, and NO is known to activate calcium-sensitive K+ channels (KCa
channels). The β-adrenoreceptor agonists (β-agonists) are the most important bronchodilators in
airway pharmacology and they are also known to activate these channels.
NO donors have been used for over a century to treat ischemia, but there is a need to develop
new, safer NO donors. The potencies and efficacies of novel NO donors, oxatriazoles GEA 3268
and GEA 5145, were compared to the older NO donors sodium nitroprusside (SNP) and 3-
morpholino-sydnonimine (SIN-1) and to the commonly used β2-agonist, salbutamol. The novel
compounds were more potent and efficient against metacholine-, histamine-, or KCl-contractions
than the old NO donors, but not as good as salbutamol in the guinea pig bronchi. In metacholine-
or KCl-contracted rat bronchial preparations, all of the NO donors were more potent and efficient
than salbutamol. The relaxations of the structurally different NO donors GEA 3268, GEA 5145,
SIN-1, and S-nitroso-N-acetyl-penicillamine (SNAP) were studied in guinea pig trachea with
selective KCa channels blockers, iberiotoxin (IbTX) and charybdotoxin (ChTX). With
metacholine contraction, all of the four compounds mediated their relaxation via the KCa
channels. Inhibition of soluble guanylate cyclase (sGS) prevented relaxation of all the NO donors
concentration-dependently indicating that the relaxation was cyclic GMP dependent.
Pretreatment with different selective K+ channel blockers in metacholine-induced contraction did
not modify bradykinin- or SNP induced relaxation in mouse trachea. However, lemakalim, an
opener of the KATP channels, relaxed trachea in a concentration-dependent manner and this could
be inhibited by the KATP channel blockers, suggesting that these channels exist in mouse trachea.
In metacholine contracted guinea pig trachea NO donors had a positive synergistic relaxing effect
with the β2-agonist salbutamol. There was no synergistic effect against contraction induced by
high KCl concentrations. The results in the presence of IbTX suggested the KCa channels were
partly involved in the synergistic relaxation. The non-selective phosphodiesterase inhibitor, 3-
isobutyl-1-methylxanthine (IBMX), could not induce any corresponding synergistic effect to the
relaxations of SNP or salbutamol alone, suggesting that the effect does not originate from
inhibition of phosphodiesterases. In the presence and absence of IBMX, as a function of time,
there was no correlation in nanomolar salbutamol- or micromolar SNP-induced changes in cyclic
nucleotides concentrations when compared to the relaxation response. Over the initial minutes,
cyclic GMP concentrations decreased, but at that time there was no change in production of
cyclic AMP levels evoked by salbutamol, SNP or their combination. The mechanism(s) of the
synergistic effect was not directly related to level of cyclic nucleotides since their levels did not
correlate with relaxation.
NO and its derivatives are important mediators that can modify relaxation of guinea pig trachea
when studied in vitro. This represents a new challenge to the development drugs: a corresponding
synergistic effect in human airways would offer new therapeutic possibilities for the treatment of
asthma.
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1. INTRODUCTION
1.1. Asthma: increasing airway inflammatory disease
Asthma is a world wide chronic airway eosinophilia, a T helper 2 cell-driven chronic
inflammatory disease, the etiology of which is not known (Holgate, 1997). There is an increase in
the incidence of asthma in western Europe (Burney, et al., 1994), and percentages of childhood
asthma in the world (see table 1, Burr et al., 1994; Pearce et al., 1993). The mortality and
morbidity associated with this disease have not appreciably declined (Sly and O'Donnell, 1997).
Asthma, if anything, has even increased among children, especially in boys. The treatment of
asthma has not changed markedly over the last two decades (Wenzel, 1998).
Country or area %
Australia 30
Caroline Islands 35
France 7
Gambia (rural) 0
India 2
Japan 0.7
New Guinea Highlands 0
New Zealand 8
Scandinavia 10
Singapore 5
Tanzania 8
United Kingdom 15
USA 13
(Alaska) 0.1
Venezuela 7
Table 1. Percentage of the childhood asthma in some countries or areas (Bonfate, 1998).
Laitinen and coworkers (1985) observed a correlation between bronchial hyperreactivity and
airway epithelial damage in asthma patients. Asthma is an inflammatory disease and treating the
patient with glucocorticoids will lessen the symptoms. However, chronic treatment with
glucocorticoids has disadvantages, especially when they have to be given by systemic
administration instead of local aerosolized delivery directly to the airways. By the mid 1990’s,
new anti-inflammatory, non-glucocorticoid treatments were introduced: cysteinyl leukotriene
antagonist, montelukast, zafirlukast, and pranlukast, and a 5-lipoxygenase inhibitor, zileuton.
Unfortunately, these did not improve the lung functions of all asthmatics (Bateman et al., 1995;
Laitinen et al., 1995; Dahlen, et al., 1998). Therefore, research has not reached its goal, and the
treatment of asthma is still seeking for targeted, anti-inflammatory therapy.
1.2. The discovery of NO
In 1980 Furchgott and Zawadzki discovered intriguing effects of acetylcholine in noradrenaline-
contracted vascular smooth muscle preparations. Its effects, sometimes relaxing, sometimes no
effect, were found to correlate with the presence of an intact endothelial cell layer. In 1987 a new
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endogenous relaxant came to the attention of the scientific world, due to the efforts of several
independent groups (Ignarro et al., 1987; Palmer et al., 1987; Khan and Furchgott, 1987). First
named as an endothelium-derived relaxing factor (EDRF), later confirmed to be NO, it was found
to play an important role in maintaining vasodilator tone, regulation of blood flow and pressure.
Later, NO was shown to inhibit cell proliferation, act as a neuromodulator, and became the most
important and extensively studied individual molecule in medicine. It is implicated in ailments
like impotence and possibly also in Alzheimer’s disease and diabetes mellitus. It plays a role in
impaired organ function and diseases, since it can be viewed as an inflammatory mediator in
several diseases such as rheumatoid arthritis, asthma and colitis.
This small compound exists in a gaseous form, and escapes detection in all but the most
sophisticated determination techniques. One common problem faced by all research groups
investigating NO, is the fact that the methods used to measure NO directly are limited and have
several inherent problems. Most of the research is done by indirect methods. Messenger RNA
production measurement of NO synthase (NOS) isozymes is an example of one of an indirect
methods. Other indirect NO measurements such as NO2- and NO3- and production of cyclic GMP
are commonly used, as well as measurements of NOS enzyme activities. Many studies have used
inhibitors of NOS enzymes and surplus of arginine, which is another approach to the study the
effects of NO, (Fig. 1).
Fig. 1) NO is produced by nitric oxide synthases that catalyze the conversion of L-arginine into
citrulline.
When the journal “Science” selected NO as "the Molecule of the Year" in 1992, by that time
6000 scientific articles had been published. By the end of 1998 already 24.000 articles had been
published, and although the peak of publications was most probably encountered in 1998, the
total number of publications in medicine is still very large with a large number of research groups
examining different facets of this fascinating molecule.
NO has a role also in airway diseases: in 1993 Alving et al., showed that the production of NO in
the airways of asthmatics is increased compared to the healthy controls. Two years later Yates et
al., (1995) together with Kharitonov et al., (1996) observed that the production of NO in the
exhaled air of asthmatics could be inhibited by glucocorticoids, anti-inflammatory drugs that had
been commonly used to treat asthma and other inflammatory diseases. However, luminal NO
concentrations are not as highly increased in asthma (2-10 times) as they are in inflammatory
bowel disease (20- to 200-fold increase) or cystitis (30- to 100-fold increase) Lundberg et al.,
(1997).
1.3. NO: a double edged sword
Not only could NO relax vascular smooth muscle, it was also able to relieve spasms of airways in
NO
L-Arginine                                    L-Citrulline
  NOS
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vivo (Dupuy et al., 1992), as well as relaxing the gastrointestinal tract (Stark and Szurszewski,
1992). Already in the mid 1990’s NO have been shown to be a double edged sword: at low
concentrations, it is a beneficial agent; but when present in high concentrations, it is a general
cytokine and a free radical inducer that through interplay with the cyclo-oxygenase enzymes
could affect also prostaglandins (Prof. Ryszard Gryglewski, personal communication 1994;
Wickelgren, 1997). Due to its two different roles in the airways, relaxant and an inflammatory
mediator; NO became a hot topic in the field of pulmonary pharmacology.
Fig. 2A) Interactions with NO and O2- between leukocytes and the endothelial cell, according to
Granger and Kubes, 1996. NO also inhibits xanthine oxidase (Fukahori et al., 1994), therefore
inhibition of NO production further induces endothelial cells to produce O2-. Guanosine
triphosphate, (GTP).
The beneficial effects of NO in the vasculature can be attributed to by oxidant stress and radical
productions: NO produced by endothelial cells penetrates to the smooth muscle cells layer, where
oxidase enzymes can generate O2-. NO traps O2- and ONOO- is generated but this is converted
into hydroxyl radical and NO2-. Under normal physiological conditions, both NO and O2- are
produced, but NO production is 2-3 fold orders of magnitude higher than that of O2- leading to
increased O2- consumption. NADPH oxidase generates O2- which is converted to hydrogen
peroxide (H2O2) by superoxide dismutases (SODs). H2O2 is degraded to water by catalases. Thus,
NOS inhibition should result in oxidant stress, with induced production of inflammatory
mediators (Kurose et al., 1995), Fig. 2A. Since NO exerts a tonic and reversible inhibitory
influence on xanthine oxidase activity, inhibition of iNOS production ultimately could lead to
production of H2O2, which is known to promote formation of platelet-activating factor
(Zimmerman et al., 1992) and to elicit an increased expression of endothelial cell adhesion
molecules e.g. P-selectin and I-CAM (Zimmerman et al., 1992).
NO
hemoglobin
NO
NO2¯
NO3¯
Oxidases O2
H2O2
NO
Endothelial
cell
L-arginine
L-citrulline
Smooth muscle
cell
cyclic GMP GTP
ONOO¯
guanylate cyclase
O2¯
+ 
O 2
OH¯
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Reactive oxygen species play important roles in several different inflammatory conditions of
airways, as the latest publications show: oxidative stress has been demonstrated to induce iNOS
in human pulmonary alveolar epithelial cells (Adcock et al., 1994), and pure oxygen exposure at
or more than 1 atmosphere can induce microvascular permeability changes and increase in iNOS
expression in the tracheal tissue of rats (Bernareggi et al., 1999). Exposure to an allergen can
induce O2- production by alveolar macrophages in allergic patients (Calhoun et al., 1992).
Parainfluenza type 3 virus-induced airway hyperresponsiveness has been shown to be associated
with epithelial damage and a decrease in NO production upon histamine challenge to guinea pigs
(Folkerts et al., 1992). Several publications show that RSNOs have profound bacteriostatic
effects (Incze et al., 1974; DeGroote and Fang, 1995). It has been suggested that the decreased
antiinflammatory activities resulting from decreased NO production would lead to decreased
RSNO production, silencing the antioxidant genes, therefore, cells could not protect themselves
when they are threatened by pathogenic bacteria (Hausladen et al., 1996), Fig. 2B.
Fig. 2B) In oxidative stress, H2O2 decreases glutathione (GSH) and runs in parallel to nitrosative
stress in Escherichia coli, but has been suggested to exist in other cells, too. In nitrosative stress
there is depletion of intracellular free GSH to GSNO (S-nitrosoglutathione). The H2O2-
responsive activator of antioxidant genes (OxyR), oxidized glutathione (GSSG). According to
Hausladen et al. (1996).
oxidative stress nitrosative stress
Sensor: oxidation Sensor: S-nitrosylation
GSH
oxyR oxyR
GSSG
thiol oxidation
H2O2
metabolizing
activity
RSNO
metabolizing
activity
GSH GSNO
thiol oxidation
H2O2 RSNO
 antioxidative genes
antinitrosative genes 
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2. REVIEW OF THE LITERATURE
2.1. Membrane potential and ion balance of smooth muscle
The lipid membrane bilayer contains transmembrane proteins that have several functions. One of
these functions is to facilitate selective ion transport into cytosol. These ion channels of animal
cell do not consume any energy i.e., ion transport mediated by ion channels is passive ion flux
depending on membrane potential (Vm) and the permeability of the channel for the particular
ions. K+ is the most important ion to affect the Vm because membrane is selectively permeable,
and most permeant to K+. When K+ starts to penetrate through the membrane, anions that had
bound to the K+ and which carry a negative charge are left behind. These anions may be proteins
that could only be actively transported or the anion could be Cl- which is much less able to
permeate through the membrane. Vm is the voltage- and ions concentration- difference across the
cellular plasma membrane. At a resting Vm, the concentration of K+ is approximately 35 times
higher inside than outside, and the concentration of Na+ is 10 times higher outside than inside.
K+, Na+, Cl- and Ca2+ are the most important ions which can affect the Vm.
The flow of ion X through a membrane channel is driven by an electrochemical gradient, which
is the sum of 1) the voltage gradient of all ions across the membrane and 2) the concentration
gradient of X. The Vm can be calculated according to Nernst equation, which is:
Vm = RT / zF(ln co/ci)
where
Vm = membrane potential
R = the gas constant, 8.3 J K-1 mol-1
T = temperature, 298 K
F = Faraday’s constant, 96500 C mol-1
z = valence of the ion
co = external concentration of ion
ci = internal concentration of ion
However, a better understanding of the Vm is obtained from the Goldman equation where
concentrations of the most important ions and their relative permeability are taken into account:
Eions = RT / F ln ((PK[K+]o+ PNa[Na+]o+ PCl[Cl-]o) / (PK[K+]i+ PNa[Na+]i+ PCl[Cl-]i))
where
P = permeability constant of particular ion
[K+]o = extracellular concentration of K+
[K+]i = internal concentration of K+
When the cytosolic and extracellular concentrations of a certain ion are used in the Nernst
equation, the resting potential of the ion can be calculated. The resting Vm can be calculated to be
very close to the equilibrium potential for K+ (EK). However, the high permeability of K+ makes
it such an important ion in determining the resting potential. Smooth muscle cells in arteries and
arterioles, in vitro, have stable Vm between -40 - -60 mV when subjected to normal levels of
intravascular pressure (Brayden and Nelson, 1992). Vm measured in vivo is in the range of -40 to
-55 mV (Hirst and Edwards, 1989; Nelson et al., 1990). The equilibrium potential for Cl- in
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guinea pig vas deferens is about -24 mV (Tomita and Iino, 1994). For a typical cell, the
equilibrium potential for Na+ is 50 to 65 mV. A positive value in the equilibrium potential
indicates ion flux into the cell, a negative value indicates ion flux out of the cell.
When the extracellular (4 mM) and intracellular (140 mM) concentrations of K+ are measured
and used in the Nernst equation, one obtains the expression:
equilibrium potential for K+  (EK ) = 8.3 x 298 / 965000 x ln (4 / 140) = -91 mV
but for Na+ equilibrium potential for Na+ is
ENa = 8,3 x 298 / 965000 x ln (142 / 14) = 59 mV
When smooth muscle is contracted by 40 mM KCl the EK will become -32 mV but as the other
ions should also be affected the Vm cannot be estimated simply by calculating EK. However, the
value is significantly higher than the resting potential.
Everywhere except adjacent to the surface of membrane, negative and positive charges are equal.
This electrical neutrality prevents billions of volts from appearing within body fluids. It also
means that a very small number of ions need to be transferred over the membrane to establish the
normal equilibrium potential. The estimation is that 1/5,000,000 to 1/100,000,000 of total
positive charges of a nerve fiber need to be transferred.
Fig. 3) Schematic representation of K+ equilibrium across the plasma membrane. If the Vm is kept
at 0 mV, there will be a strong outward flux of K+ ions (A). When the Vm is kept at -90 mV the
flux of K+ ions through the channels is balanced (B).
A B
extracellular
(K+) 4 mM 4 mM
K+ K+K+  selective
channel
K+K+
intracellular
(K+) 140 mM 140 mM
membrane
potential 0 mV -90 mV
A B
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2.2. Agents inducing smooth muscle contraction
2.2.1. Role of calcium in the contraction of smooth muscle
In the depolarized state, there are only a few open calcium channels out of the several thousand
calcium channels. The two most important factors affecting smooth muscle contraction are
[Ca2+]i and the contractile machinery’s sensitivity to calcium. Ca2+ influx is achieved by
contracting agonists that act through their specific receptors or through the opening of non-
selective cation channels which depolarize the plasma membrane. Only a few Ca2+ ions are
needed for the triggering effect. These can easily penetrate into the cell since the concentration
gradient of Ca2+ over the plasma membrane of cell is large, 10.000 times higher extracellularly
when compared to the cytosolic Ca2+ concentration.
Contracting agents induce hydrolysis of membrane phosphatidylinositol-(4,5)-bisphosphate. This
is a very potent contraction signal and will further induce an increase in inositol-(1,4,5)-
triphosphate (IP3) and diacylglycerol (DAG). These will induce release of [Ca2+]i and activation
of protein kinase C (PKC), respectively. When the cytosolic Ca2+ concentration is increased over
the physiological level, this will activate at least two families of channels, the IP3 receptors in the
plasma membrane, and ryanodine receptors in the sarcoplastic membrane. Activation of the
ryanodine receptors induces excitation-contraction coupling and Ca2+-induced Ca2+-release
processes that will increase the cytosolic Ca2+ concentration much more than the extracellular
Ca2+ flux.
2.2.2. Metacholine-induced contraction
Metacholine is a derivative of acetylcholine (Fig. 4). Acetylcholine is released from nerve
terminals and this neurotransmitter will bind to muscarinic receptors in the membranes of the
target cells. Acetylcholine is catabolized by choline esterases, endogenous enzymes which
inactivate the stimulating signal. Choline esterases cannot catabolize metacholine, and thus
metacholine can maintain a stable contraction in the smooth muscle preparation.
Fig. 4) Chemical structures of commonly used muscarinic agonists.
Acetylcholine H3C
=
=
=
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  O 
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 CH3 CH3
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Metacholine is most selective for muscarinic type 3 (M3) receptors. At high concentrations it
binds to M2 receptors. M2 or M2(-like) receptors are found prejunctionally in parasympathetic
cholinergic nerve endings, in which they control neurotransmitter release (Fryer and Maclagan,
1984; Kilbinger et al., 1991; and ten Berge et al., 1993). M2 and M3 receptors are found in
smooth muscle (Roffel and Zaagsma, 1995). M4 receptors have been detected only in rabbit
alveolar walls in lung, but not in other species (Roffel and Zaagsma, 1995). Dysfunctional
prejunctional muscarinic inhibitory autoreceptors are found in human patients with mild asthma
(Minette et al., 1989) and in guinea pigs in trachea (Fryer and Jacoby, 1993).
It has been confirmed that the M2 receptors are coupled to inhibition of adenylate cyclase (AC),
through an inhibitory of Gi protein (Gi is subgroup of G proteins, inhibitory G). Since the KCa
channels activation has also been shown to be involved with a Gs protein (Gs is subgroup of G
proteins, stimulating G), functional antagonism of the β-receptor-induced relaxation and
muscarinic receptor-induced contraction can be explained, and has been shown in canine species
(Torphy et al., 1983) as well as in guinea pigs (Kume and Kotlikoff, 1991), (Fig. 5).
Fig. 5) Balance of contraction and relaxation in smooth muscle is dependent on parasympathetic
and sympathetic activation. β-Agonists activate AC through a subgroup of G proteins, Gs protein.
M2 and M3 receptors can modulate the contraction. M3 receptors are coupled to Gq, that enhance
production of IP3 and DAG, leading to an increase in [Ca2+]i. However, M2 receptor activation is
mediated through a Gi protein which will inhibit AC. According to Eglen et al., (1994).
2.2.3. KCl-induced contraction
Vm of smooth muscle primarily regulates muscle contractility through alterations in Ca2+ influx
via voltage-operated Ca2+ channels (VOC) (Nelson et al., 1990). An increase in the extracellular
  Gs Gi    PLC
intracellular
adenylate
cyclase
    Gq
  cyclic AMP IP3  and  DAG
 relaxation contraction
(+) (-) (+)
 extracellular     β-adrenoceptor M3 receptor
acetylcholine
 β-agonist
 M2receptor
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K+ (Ke) will change the Vm and this will increase open probability (Po) of other important
channels such as the Na+, Cl-, and Ca2+ channels. When these channels open they will again
change the Vm and in an excitable cell the change in energy of the stimulus will be bigger than
the change in the response (Fig. 6).
Fig. 6) Measurement of the passive electrical properties of a cell membrane: different response
curves. A) curves 1 and 2 represent stimuli that induced hyperpolarization, e.g. changed the Vm to
a more negative value than before the experiment. Curves 3 and 4 represent stimuli that
depolarized the cell. Curve 4 represent the curve that induced an action potential in the excitable
cell, the change of the Vm is not correlated with the magnitude of the given stimulus. B)
Represents the currents obtained by the stimulus: currents of 1, 2 and 3 are in correlation with the
Vm response of the cell, whereas the stimulus in 4 was increased and the change in response was
not related to the change of the stimulus.
Depolarization of the cell membrane is achieved by increasing Ke over the threshold level which
is approximately 40 mM concentration of K+. Opening the K+ channels can no longer close VOC.
Since the extracellular concentration of Ca2+ is high, Ca2+ will enter the cell and induce
contraction. Finally, the Vm achieves a value such that Na+ and Cl- channels become closed.
However, in the permanent presence of high Ke most of the K+ channels cannot affect the Vm
before the Ke concentration is decreased and the VOC become closed. When Ke is decreased,
gradually these K+ channels will be effective again as the Vm changes closer and closer to the
resting potential and the cell membrane becomes hyperpolarized.
One way to study a possible K+ channel opener is to increase the Ke to 40 mM level. Allen et al.
(1986) showed that cromakalim, an opener of the KATP channels, could relax 20 mM K+-induced
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contractions but not those induced by 124 mM K+, a situation in which the Ke becomes close to
the intracellular K+ concentration. Cromakalim can induce hyperpolarization and increase the
efflux of 86Rb+ in guinea pig trachea (Allen et al., 1986). However, cromakalim does not affect
the cyclic nucleotide levels nor can it inhibit phosphodiesterases (Berry et al., 1991). The VOC
inhibitor, verapamil, is a several times more potent relaxant against 124 mM K+ contraction than
against carbachol-induced contraction (Nielsen-Kudsk et al., 1986). Carbachol induced
contraction in guinea pig trachea in Ca2+-free Krebs buffer containing EGTA, but still very high
concentration (124 mM) of K+ in the same buffer induced only minor contraction (Nielsen-Kudsk
et al., 1986). This is possibly the reason why a classical L-type VOC antagonist such as
nifedipine is a potent relaxant against high K+-induced contraction but less potent against
spasmogen-induced contractions (Nielsen-Kudsk et al., 1986; Li et al., 1997), (Fig. 7).
Fig. 7) Increase in Po of the VOCs in function of Vm and increase in Ke concentration. At Ke
concentrations lower than 40 mM Vm will be sufficiently negative, the VOCs will be closed and
K+ channel opening can induce relaxation. Increasing the Vm will open the VOCs and let the
extracellular Ca2+ to flux into cells, inducing depolarization.
2.3. Relaxing mechanisms of smooth muscle
2.3.1. β-Adrenergic agonist -induced relaxation
At least three different β-receptors (β1, β2, β3) have been found and cloned at present (Dixon et
al., 1986; Frielle et al., 1987; Emorine et al., 1989). These three receptors differ noticeably from
each other. The most important receptor in the relaxation of airway smooth muscle is the β2-
receptor. The β1-receptors are most important in the cardiac muscle. The human β3-receptors are
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expressed in adipose tissue and have only 50% homology in amino acid sequence to β2 and β1
(Emorine et al., 1989). β3-receptors have not yet been detected in lung (Kriff et al., 1993; Thomas
and Liggett, 1993).
By the use of fluorescence spectroscopy and the β2-blocker carazolol, the ligand-binding site of
the receptor has been shown to exist inside the lipid bilayer, between the seven transmembrane
helixes, 11Å deep (Tota and Strader, 1990).
When a β-agonist binds to its receptor, it will induce a conformational change in the G-protein’s
α-subunit. This unit binds to GTP together with the other subunits of GS, such as β and γ.
Activation of the α-unit will induce a signal to AC, a membrane bound intracellular enzyme that
will catalyze the conversion of ATP to cyclic AMP. Production of cyclic AMP will activate
cyclic AMP dependent PK (PKA). PKA will further phosphorylate several different intracellular
proteins that once activated lead to muscle relaxation. PKA inhibits phosphorylation of myosin
light chain kinase (MLCK) (Gerthoffer, 1986), activates Na+, K+ ATPase (Gunst and Stropp,
1988), promotes Na+, Ca2+ exchange (Twort and Breemen, 1989) and inhibits phosphoinositide
(PI) hydrolysis (Hall and Hill, 1988; Madison and Brown, 1988). PKA will also finally
phosphorylate the KCa channels (Fig. 8).
Fig. 8) The molecular mechanism of β-agonist receptor activation. Contracting phosphoinositol
(PI), Ca2+ entry is balanced by removal of Ca2+ out of the cell by Na+/Ca2+ exchange pump
(Na+/Ca2+ exchange), for the control of intracellular Na+- and K+- balance there is transmembrane
β2-Agonist
β2 AR
K+
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pump exchanging 3 Na+ ions for 2 K+ ions powered by the energy of ATP (Na+-K+- ATPase),
myosine light chain kinase (MLCK). According to Barnes (1995a).
Kume et al. (1989) have shown using the patch clamp technique that the KCa channels of rabbit
tracheal smooth muscle are activated by extracellular application of the β-agonist, isoprenaline,
or intracellular application of PKA. Later his group showed that the KCa channels can be
activated directly by isoprenaline, through the G-proteins αS subunit without there being any
change in cyclic AMP (Kume et al., 1992; 1994). It has been suggested that this may be clinically
important in the treatment of asthmatics: very low concentrations of β-agonists could be used
without tolerance to β-agonists (Barnes, 1995b). It must be remembered that it has been
surprisingly difficult to demonstrate desensitization of the bronchodilator effect of β-agonists in
asthmatic subjects, but small effects have been observed in normal subjects (Tattersfield, 1985).
However, although the use of β2-agonists for the treatment of acute asthma attacks is safe and
effective (Janson et al., 1988), the use of β2-agonists in maintenance therapy has been debated
since the late 80’s. An increase in asthma mortality in New Zealand was found to be associated
with an increase in the use of fenoterol (Crane et al., 1989) and possibly other short acting
inhaled β2-agonists (Ullman, 1995).
2.3.2. Endogenous NO production and NO-induced relaxation
NO is produced by nitric oxide synthases that catalyze conversion of L-arginine into citrulline.
Three different isoenzymes are known: neuronal form (nNOS, type I NOS), inducible form
(iNOS, type II NOS), and constitutive form (cNOS, type III NOS). cNOS has also been
designated as eNOS since it was discovered in the vascular endothelium. The constitutive form
can also be somewhat inducible as cNOS is induced in chronic exercise (Sessa et al., 1994).
cNOS can release picomoles of NO within seconds or minutes (Moncada, 1992) when stimulated
by agonists such as acetylcholine, bradykinin, platelet activating factor and histamine. The NO
produced by iNOS is in the nanomolar range.
Immunohistochemical studies of NOS subtypes I NOS II NOS III NOS
in airways nNOS iNOS cNOS References
Vascular endothelium of bronchial circulation x Shaul et al., (1994)
Cholinergic nerves x Fischer et al., (1993)
Epithelial cells x Asano et al., (1994)
Immunological and inflammatory stimuli x Geller et al., (1993)
Epithelium of bronchi and trachea of rat and human x x Kobzik et al., (1993)
Increase in asthmatic human airway epithelium x Hamid et al., (1993)
Eosinophils and macrophages x Giaid et al., (1998)
Table 2. Subtypes of NOS enzymes found in airways.
In airways, NO is produced by epithelial- and endothelial- and inflammatory cells, and sensory
nerves (table 2). NO production has been suggested to play a central role in oxygen-induced
vasodilatation (Johns et al., 1989; Cornfield et al., 1996). Quite recently it has been shown that
oxygen can regulate type II NOS kinetics in normal humans in vivo (Dweik et al., 1998). NO
production was shown to be proportional to the inspired oxygen levels throughout the physiologic
range (Dweik et al., 1998). In normal human airways in vivo type II NOS is the major isozyme
23
(Guo et al., 1995).
The bronchodilator effects of nitrates have been known for more than half a century (Goodman
and Gilman, 1936). NO and its redox-related forms can react with proteins, carbohydrates, lipids,
and nucleic acids. In general the reactions with enzymes lead to their inactivation, through heme
groups and thiols, but a group of guanylate cyclases (GC) is activated, and these can be divided
into two types: receptor-containing particulate (pGS), and the soluble intracellular enzyme (sGC).
NO activates an intracellular enzyme, sGC, but the membrane associated form, pGS is activated
by natriuretic peptides (atrial-, brain-, and c-natriuretic peptides) and vasoactive intestinal
peptide. NO appears to activate the enzyme by binding to the heme group. The other alternative
is that NO or its redox-related forms could interact and modify other sites of sGC (Brandwein et
al., 1981; Ignarro et al., 1982). NO signalling can include metal or thiol centers of proteins, and
therefore, NO-related species are capable of causing postranslational modification, for example
they can affect membrane ion channels of N-methyl-D-aspartate receptor (Lipton et al., 1993),
and modify signalling proteins like p21ras (Lander et al., 1995), and PKC (Gopalakrishna et al.,
1993).
NO-mediated signalling can modulate transcription through activation of universal transcription
factors, such as NF-κB and activation protein-1 (AP-1). NF-κB can be affected through p21ras
(Lander et al., 1995), and induction of AP-1 has been appeared to be partly dependent on cyclic
GMP (Pilz et al., 1995), the secondary signalling molecule of NO.
Activation of GC leads to production of cyclic GMP. This is an older discovery than NO, since
several years after the discovery of cyclic AMP, it was shown that hormones and other agents
like nitrovasodilators could induce the formation of cyclic GMP in many tissues. Katsuki et al.
(1977a and b) observed that the increased cyclic GMP production could cause relaxation.
From this step forward there is the possibility of cross-talk between the two cyclic nucleotide
signalling pathways: activated GS can synthesize cyclic AMP (Mittal et al., 1979). Other steps
are 1) activation of PKs (see 2.3.4); and 2) degradation of cyclic nucleotides by
phosphodiesterases (see 2.3.5).
2.3.3. Bradykinin-induced relaxation
Endogenously derived vasodilatory bradykinin is a nonapeptide that has been shown to be an
important mediator in hypertension. Its actions are mediated through bradykinin B1 or B2
receptors. The former receptor may be involved in chronic inflammation (Ahluwalia and Perretti,
1999), but the role of B2 receptors has been studied in more detail. Bradykinin has been shown to
induce relaxation through production of prostaglandins and by production of NO or NO-related
substance in several different smooth muscle preparations, such as in pig coronary artery (Cowan
and Cohen, 1991), guinea pig coronary vasculature (Vials and Burnstock, 1992), and in guinea
pig trachea (Schlemper and Calixto, 1994). In guinea pig trachea, both prostaglandins and NO
induce the relaxation, and the prostaglandin responsible for bradykinin-induced relaxation is
apparently prostaglandin E2. In BALB/c mouse tracheal smooth muscle the relaxant action by
bradykinin has not been shown to activate NO pathway (Heuven-Nolsen et al., 1997; Li et al.,
1998b), instead prostaglandin E2 has been suggested to mediate the relaxing effect.
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2.3.4. Activation of protein kinases
There are a number of different intracellular kinases currently known to mediate signals inside
the cell. One of the targets is a cyclic nucleotide-regulated PK. Cyclic AMP activates protein
kinase A (PKA), and cyclic GMP activates selectively, but not specifically, protein kinase G
(PKG). PKG can be divided into two different classes, type I PKG and type II PKG. Type I PKG,
of which α and β forms exist, is widely expressed in mammalian cells (Walter, 1988). Smooth
muscle cells contain the most abundant levels of type I PKG in both α and β forms, but type II
PKG is mostly expressed in intestinal epithelial cells (DeJong, 1981).
High concentrations of cyclic AMP can also activate PKG (this is called “cross over”), which has
been demonstrated in rat aortic smooth muscle cells in culture (Lincoln and Cornwell, 1993).
Low concentrations of NO activate PKG, phosphodiesterases, and ion channels; but high, over 1
µM, concentrations of NO activate PKA, and may produce ONOO-, and induce ADP-
ribosylation. The continuous presence of NO donors in cultured bovine aortic smooth muscle
reduced expression of PKG (Lincoln et al., 1998). Therefore, the pathophysiological effects of
NO have been suggested be due to PKA activation, followed by down-regulation of PKG
(Lincoln et al., 1998). In isolated bovine tracheal smooth muscle cells it has been shown that one
role of PKG is to decrease [Ca2+]i (Felbel, 1988), but the mechanism still has to be defined. When
various smooth muscle cells are studied, the complexity of PKG in intracellular actions is
revealed. Increase in [Ca2+]i may be prevented by inhibition of phospholipase C (PLC) activation,
by IP3 receptor gating. PKG may also stimulate Ca2+ removal by activation of the KCa channels or
by phosphorylation of phospholamban, which is annealed to the sarcoplastic reticulum at the
cytosolic side and can stimulate Ca2+-ATPase activity inside the reticulum. PKG may also
prevent the contractile protein function and inhibit L-type Ca2+ channels (Méry et al., 1991). The
role of PKA or PKG in the relaxation of smooth muscle preparations has also been difficult to
evaluate for several reasons:
1) lack of cyclic AMP and cyclic GMP analogues that would be selective inhibitors for their PKs.
2) insufficient penetration of the analogues into intact cells.
3) lack of analogues that would not be vulnerable to the degradation by phosphodiesterases.
Only from the mid 1990’s have such inhibitors of PKs been available, such as the Rp isomer 8-(4-
chlorophenylthio) guanosine 3’,5’-cyclic monophosphorothioate (Rp)-8-pCPT-cyclic GMPS
(Butt et al., 1994), and presently one of the best seems to be the Rp isomer 8-bromo-βphenyl-
1,N2-ethenoguanosine 3',5'-cyclic monophosphorothioate, (Rp)-8-bromo-PET-cyclic GMPS (Butt
et al., 1995). These compounds have not been reported to be studied in airway smooth muscle
relaxation, although one study in rat tail arteries exists (Butt et al., 1995). The PKA inhibitor,
(Rp-8-pCPT-cyclic AMPS) could not inhibit salbutamol-induced relaxation at 100 µM
concentration when incubated for 40 min in contracted guinea pig tracheal preparations.
However, the PKG selective inhibitor, (Rp)-8-Br-pCPT-cyclic GMPS, could inhibit SNP- but not
salbutamol-induced relaxation in the same experimental conditions (unpublished results, Vaali et
al.). However, synthetic stereospecific substrates were able to inhibit PKA or PKG in micromolar
concentrations in purified enzyme preparations in vitro (Yan et al., 1996). It is possible that the
above mentioned inhibitors cannot be used in organ bath studies of smooth muscle relaxation.
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2.3.5. Inhibition of phosphodiesterases
There is a large family of cyclic nucleotide hydrolyzing enzymes which terminate the
intracellular signals produced by receptor agonists. This family is called phosphodiesterases, and
at the moment molecular biology has classified 9 different isoenzymes of which 7 have been
isolated in protein form (Table 3). Members of one isoenzyme family (designated by the Roman
numerals) share 20-25% sequence homology with members of another. One family may contain
two or more related subfamilies (designated with a capital letter) deriving from similar, 70-90%
homology, but distinct genes. Subfamilies may have multiple members (designed with Arabic
numerals) that are produced by alternative messenger RNA splicing.
It has also been suggested that PKA directly activates and phosphorylates phosphodiesterase type
III isolated from adipocytes and platelets in vitro (Houslay and Kilgour, 1990; Manganiello et al.,
1990), respectively. In airway smooth muscle cells, according to the model presented by Pyne et
al., (1996) activation of PKA induces inhibition of phosphodiesterase type III and increase in
cyclic AMP.
Phosphodiesterases type III and IV hydrolyze exclusively cyclic AMP, but phosphodiesterase
type V, which has been isolated in lung, vascular- and bronchial smooth muscle can hydrolyze
only cyclic GMP (Souness et al., 1989). In airway smooth muscle, the existing phosphodiesterase
subtypes and selectivity and potency of the available phosphodiesterase inhibitors restrict
information to phosphodiesterase types III, IV and V. In guinea pig trachea, only types III and IV
were identified with certainty (Harris et al., 1989), but in canine and bovine trachea, five different
isoenzyme families (Iβ, II, III, IV, and V) have been found (Torphy and Cieslinski, 1990;
Giembyzc and Barnes, 1991; Shahid et al., 1991). Little is known about the regulation of
phosphodiesterase isoenzymes in bronchial smooth muscle.
Phosphodiesterase
family
type cyclic AMP
Km (µM)
cyclic GMP
Km (µM)
Selective inhibitors References
Ca2+/calmodulin
-stimulated
I 2-70 2-20 Vinpocetine Souness et al., 1989
Cyclic GMP-stimulated II 30-100 10-30 MEPI Müller and Nennstiel,
1992
Cyclic GMP-inhibited III 0.1-0.5 0.1-0.5 Siguazadon, SK&F 94120 Murray et al., 1990
Cilostamine Hidaka et al., 1984
Milrinone Harrison et al., 1986
Enoximone Kariya and Dage, 1988
Cyclic AMP-specific IV 0.5-2 >50 Rolipram Nemoz et al., 1989
Ro 20-1724 Nemoz et al., 1989
Denbufylline Nicholson et al., 1989
Cyclic GMP-specific V >40 1.5 Zaprinast Souness et al., 1989
Photoreceptor VI >500 17-20 Zaprinast Gillespie and Beavo,
1989
Rolipram-insensitive, VII 0.2 - - -
cyclic AMP-specific
Table 3: Phosphodiesterase isoenzymes types, the Km values for cyclic AMP and cyclic GMP, and the type-selective
inhibitors. Nomenclature based on Beavo and Reifsnyder, (1990). The phosphodiesterase types VIII and IX have
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only been sequenced but no selective inhibitors are known.
It has been shown that the α-subunit of cone phosphodiesterase type VI is isoprenylated (Li et al.,
1990). A lipid molecule such as isoprenoids can anchor proteins to membranes, and this has been
suggested together with postranslational modification of phosphodiesterase subtypes to ensure
their compartmentalization within the cells.
2.3.6. Fine tuning of intracellular signalling by protein kinases, phosphodiesterases and
cyclic nucleotide compartmentalization
There are two different signalling molecules, cyclic AMP and cyclic GMP, for several different
tasks, such as gluconeogenesis, glycogenolysis and lipogenesis. These nucleotides are also
involved in secretory processes, learning, ion channel conductance, pro-inflammatory cytokine
production and action, differentiation, apoptosis, growth control as well as in muscle contraction
and relaxation. The termination of the action is also complex: there are around 30 forms of
different phosphodiesterases, when all the subtypes of the different isoenzymes are counted that
hydrolyze cyclic AMP alone. Furthermore, different isoenzymes of PKA and PKG exist. This
kind of multiplicity permits
1)  intracellular targeting,
2)  cross-talk between other signalling systems
3) possibility to control the threshold level of activation by the second messengers, cyclic AMP
or cyclic GMP.
The threshold level can be controlled by increasing the cyclic nucleotide production or
degradation i.e. by modulating high or low cyclic nucleotide conditions. In the high cyclic
nucleotide condition, the concentration of cyclic AMP is controlled by high phosphodiesterase
activity, but there is also high basal activity of the cyclic AMP producing enzyme, adenylate
cyclase (AC). This case generates a futile cyclic AMP cycle. In the other scenario, in low cyclic
nucleotide condition, cyclic AMP is produced with low AC activity, but the degradation level of
phosphodiesterases is very low, it will however, lead to moderate cyclic AMP concentration. The
threshold level of PKA activation is low, and the final outcome is domination of AC through
stimulus activation. The basal cyclic AMP turnover has been suggested to be low in intact
airways smooth muscle preparations. However, although the procedures for assessment of the
turnover are well known, they have not been utilized in airway smooth muscle (Souness and
Giembyzc, 1994).
Discrepancies in the cyclic AMP, PKA and relaxant responses evoked by forskolin and
isoprenaline have led to the proposal that, in canine trachea, various components of the cyclic
AMP / PKA cascade exist in distinct subcellular compartments (Zhou et al., 1992).
Different signalling molecules have also been suggested to be compartmentalized. One such
example is two coupled receptors acting on one AC (Faux and Scott, 1996; Rubin, 1994) Another
example is the non-uniform intracellular distribution of cyclic AMP (Hempel et al., 1996). Figure
9 presents the theoretical compartmentalization of cyclic AMP and its phosphodiesterases.
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2.3.7. Interaction of drugs
There are some studies in the literature in which the combination of two different drugs has been
studied, but in many cases the terminology concerning interaction of drugs is erroneously
described. The reason for this is the variable use of the terms in different countries during the
history of pharmacology. An additive effect has been used as a synonym for zero interaction and
overadditive effect for synergism. Additive effect of interaction is often confused with
overadditive effect. However, there is no need to define more than three classes of interactions:
synergy, zero interaction, and antagonism.
Synergy theories were developed in 1950’s by Ariëns et al., (1956a, b). Also the studies of Pöch
and Holzmann, (1980) and review of Berenbaum (1989) explain the calculation of interaction of
two or more drugs. An interaction can be defined as the effect of a combination of agents that
differs from that expected, from their theoretical, concentration-response curves alone. The
commonly used approaches for analyzing interactions are as follows:
1. Construction of iso-effect curves, isoboles
2. Summation of effects
3. Multiplication of surviving factors
4. Version of isobole method using two limiting isoboles
5. Measurement of effect of a fixed concentration of drug B on the concentration-response curve
of drug A
6. Calculation of the effect of a zero-interactive combination from the law of mass action
7. Comparison of the effect of combination with that of its constituents
It must be carefully considered which of the cases can be used to study a particular interaction.
For solving this problem, the review of Berenbaum (1989) is recommended.
Here we use both the isobole method and that of Pöch and Holzmann (1980), i.e. the method 5
above. We presume, as has been previously shown by Kume et al. (1989) and by Bolotina et al.
(1994), that both β2-agonists and NO activate the KCa channels, and therefore, our study presents
AC
PDE PDE
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PDE
PDE cAMP
cAMPcAMP
cAMP
cAMP
Fig. 9) Cyclic nucleotides could be
more vulnerable to degradation in
certain areas of cytosol. Some of the
subtypes of phosphodiesterase
isoenzymes (PDE) may be more
active or their number could be
significantly higher in particular
area. This would allow different
agonists to activate different
signalling cascades although the
signalling molecules as such are the
same.
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the case of mutually exclusive agents with sigmoid concentration-response curves. In the latter
case, the construction of isoboles (1) is a valid method, although it is also a general method for
analyzing interactions between agents, irrespective of their mechanism of action.
The theoretical interaction of the drugs is calculated, and compared to the experimental result of
the combination. In the case where the experimental effect is more marked than that of the
theoretical effect, the effect of drug B can potentiate, that is, induce a synergistic effect on drug
A’s effect. When the theoretical effect is calculated, the effect of drug A in concentration Y is
added to the effect received from a known concentration X of drug B.
2.4. K+ channels
The function of the K+ channels in excitable cells is to stabilize the Vm. These channels set the
resting potential, keep fast action potentials brief, and terminate periods of intense activity (Hille,
1992). There is a great variety of different K+ channels that are coded by numerous genes, and by
alternative splicing produce variants of one gene. K+ channels are composed of multiple subunits
of dimers or tetramers that may coassemble to form distinct channels. It is therefore
understandable that it is not easy to perform selective studies. Both in pharmacological and in
electrophysiological studies into K+ channels, non-selective inhibitors, such as
tetraethylammonium (TEA), procaine, quinine, and Cs+ have been used. Selective K+ channel
inhibitors or activators are interesting targets for the pharmaceutical industry, especially when
more ion channel-defective disease states are identified.
2.4.1. Calcium-sensitive K+ channels
Calcium-sensitive K+ channels (KCa channels) are large conductance K+ channels (also called
maxi-K+ channels or BK channels). By the use of patch-clamp measurements, they have been
identified to be the major contributors to the cellular membrane conductance of K+ (Inoue et al.,
1985; Benham et al, 1986). The conductivity has been estimated to be 250 pS / channel. The
fraction of time that the KCa channels are open (the open-state probability, Po) in rabbit jejunum
and in guinea pig mesenteric artery, increases 2.7 fold per 12-14 mV depolarization (Benham et
al., 1986). An increase in Ca2+ entering the cell will also cause an elevation of Po of the KCa
channels. The BK channels are blocked by the scorpion toxins, charybdotoxin (ChTX) and
iberiotoxin (IbTX).
When the studies with patch clamping started, large-conductance KCa channels were found in
nearly every vertebrate excitable cell (Hille, 1992), and it took several years to recognize small-
conductance KCa channels (SKCa) and intermediate (IKCa) channels that have different properties
(Romey and Lazdunsky, 1984; Pennefather et al., 1985; Blatz and Magleby, 1986, 1987). The
sensitivity of the SKCa channels is only 10-100 nM to Ca2+, but BK channels need 1-10 µM Ca2+
for their activation (at -50 mV). For commonly used external TEA, the SKCa channels are
resistant (Rudy, 1988 and Latorre et al., 1989). Apamin, which was isolated from honey bee
venom, can be used as the blocker of SKCa channels (Hugues et al., 1982). SKCa channels show
little or no voltage dependence, and their single-channel conductance is 4-14 pS (Hille, 1992).
KCa channels have been cloned from the Drosophila slowpoke locus (Atkinson et al., 1991), and
from human HEK 293 cells (Gribkoff et al., 1996). KCa channels have six hydrophobic segments
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(S1-S6) spanning the membrane similar to KV channels. These contain the pore and sense the
voltage. In addition to this, KCa channels contain four conserved segments (S7-S10) that may be
involved with [Ca2+]i sensing.
At the resting Vm the membrane is hyperpolarized and the K+ channels are closed. When the
membrane becomes depolarized, smooth muscle cells will contract. This will open the KCa and
the KV channels. Relaxing agents will further increase the open probability of K+ channels. When
most of the K+ channels open, other ion channels like the Na+ and Ca2+ channels will be closed,
because K+ channels by their equilibrium potential for K+, and by their high number, are
dominating the Vm of the cells (Fig. 10). Therefore, it is not surprising that the KCa channels have
been shown to be important in the relaxation of different smooth muscle cell types in several
animal species.
Some of the reasons for the importance of the KCa channels are: 1) the conductivity of the
channel is high, 2) the sensitivity to [Ca2+]i concentration, 3) the sensitivity to Vm, 4) the
equilibrium potential for K+ in relation to the Vm, and 5) the great number of these channels at the
plasma membrane of smooth muscle cells.
Fig. 10) Control of opening of the KCa and KV channels in relation to Vm. Voltage-dependent K+
channels (KV channels). According to Nelson et al. (1990).
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2.4.2. ATP-sensitive K+ channels
The whole cell and single-channel studies of ATP-sensitive K+ channels (KATP channels) have
been hampered by the low density of these channels (in the range of 300-500 channels / cell or 1
channel / 10 µm2) and by channel “run-down” during cell isolation and patch excitation. KATP
channels in coronary arteries appear to exhibit at least three different conductance levels (Ottolia
and Toro, 1993). ATP inhibits and ADP increases KATP currents (Ashcroft and Ashcroft, 1990).
The Po of the KATP channels exhibits little voltage dependence (Noma, 1983; Ashcroft and
Ashcroft, 1990).
Sulphonylureas, such as glibenclamide and glipizide, block selectively the KATP channels, and are
used as antidiabetic drugs that increase insulin release from pancreatic β-cells through membrane
depolarization (Ashcroft and Ashcroft, 1990). Cromakalim, lemakalim, (the active enantiomer of
cromakalim) and pinacidil are activators of the KATP channels, and they have been shown to relax
airway, intestinal, and uterine smooth muscle (Cook, 1988) suggesting that the KATP channels
exist in many types of smooth muscles.
Recent studies suggest that the KATP channels play a pivotal role in the regulation of
microvascular caliber in the coronary circulation (Ishizaka and Kuo, 1996; Ishizaka and Kuo,
1997). It has been demonstrated that atrial natriuretic peptide and NO donor isosorbide dinitrate
activate the KATP channels of vascular smooth muscle cells (Kubo et al., 1994).
The potency of openers of the KATP channels to act as inhibitors of histamine-induced
brochospasm in vivo is greater in hyperreactive than in normal animals (Chapman et al., 1992). In
human airways in vitro, an opener of the KATP channels, HOE 234, has been shown to be a very
potent bronchodilator, its EC50 is 11 nM (Miura et al., 1993). However, HOE 234 is a clearly
inferior relaxant to salbutamol in guinea pig tracheal preparations. In 1 µM metacholine
contraction of guinea pig trachea, 3.3 µM HOE 234 barely achieved a EC20 but in the same
experiments the EC50 of salbutamol is 0.02 µM (Redemann et al., 1995).
2.4.3. Delayed rectifier K+ channels
Voltage-dependent, delayed rectifier K+ channels (KV channels) open when the Vm of the cell is
depolarized. They are important in the repolarization phase of the action potentials in many
excitable cells (Hille, 1992). Only very small change in the Vm induces a major change in the Po
of the KV channels (Volk et al., 1991). The Vm is influenced by activation of the KV channels
because of the channels dependence to the Vm and the high number of the KV channels in a cell
(1,000 - 10,000 channels/cell). Airway smooth muscle generally is an electrically quiescent tissue
(Kirkpatrick, 1975) that depolarizes during activation in a graded fashion, and the KV channels
probably act mainly to limit the Vm of the smooth muscle cells (Hirst and Edwards, 1989).
These channels have been studied in the presence of 4-aminopyridine (4-AP), but 4-AP has been
shown to possess muscarinic receptor activity, which has led to the use of 4-AP in combination
with atropine. It has been suggested that 4-AP can induce neural acetylcholine release from
muscarinic receptors in rat striatal slices (Drukarch et al., 1989). 4-AP increased the histamine-
induced contraction in guinea pig, but not KCl, or carbachol-induced contractions (Isaac et al.,
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1996). In mouse tracheal preparations, 4-AP increased KCl- or metacholine-induced contractions
but this may be explained by 4-AP indirect or direct muscarinic action (Li et al., 1998a).
2.4.4. Inward rectifier K+ channels
The inward rectifier K+ channels (KIR channels) differ from all of the other K+ channels studied in
that they permit Ke to enter into the cell in a larger current than intracellular K+ flux is let out
when the Vm is controlled, e.g. by voltage clamp of the cell. The KIR channels are activated by
membrane hyperpolarization, in contrast to KV channels and KCa channels that are activated by
membrane depolarization. The activity of KIR channels is a function of both Vm and Ke
concentration (Edwards et al., 1988; Quayle et al., 1993). Therefore, the balance of K+ flux is
more complicated, and this should be kept in mind when the results of this study are evaluated.
The importance of the KIR channels is incompletely understood in smooth muscle, but their role
in tissue other than smooth muscle include regulating the resting Vm and limiting electrogenic
Na+ and K+ pumping membrane protein (Na+-K+-ATPase) and decreasing cellular K+ loss which
leads to energy expenditure during sustained depolarization (Hille, 1992).
2.5. Characterization of the compounds used in the study: different NO donors
Nitrovasodilators have been in clinical use for more than a century. Organic nitrates like
nitroglycerin undergo enzymatic degradation to generate NO. Some compounds need reduction
and others oxidation to release NO. Some compounds release NO quickly, some continuously
over a long period. The bolus nature of NO donation would most probably be harmful in the case
that NO donors are used to treat patients. This is because superoxide (O2-) and O2 react with NO
to produce several different radicals (Feelisch and Stamler, 1996). At high concentrations, in an
uncontrolled way, NO can react with proteins and lipids and produce radical cascades that would
induce reactions similar to several disease states.
Many NO donors are vulnerable to light, low pH and heat, and nitrite (NO2-) is the major
decomposition product in aerobic aqueous solutions (Feelisch, and Stamler, 1996). Due to these
differences in NO donation, several types of NO donors were used in this study and they are
introduced here shortly. For more detailed information the review of Feelisch and Stamler, (1996)
is recommended.
Derivative Abbreviation
Nitroxyl anion NO-
Nitrosonium NO+
Nitrogen dioxide NO2
Peroxynitrite ONOO-
Nitrite NO2-
Nitrate NO3-
Nitrosothiols RSNO
Table 4: Derivatives of NO.
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Oxatriazoles. The novel sulfonamide NO donors GEA 3268, (1,2,3,4-oxatriazolium, 3-(3-chloro-
2-methylphenyl)-5-[[(4-methoxyphenyl)sulfonyl]amino]-, hydroxide inner salt) and GEA
5145, (1,2,3,4-oxatriazolium, 3-(3-chloro-2-methylphenyl)-5-[(methylsulfonyl)amino]-,
hydroxide inner salt) are both derivatives of an imine, GEA 3162, that is an NO donor; and
sulfonamide GEA 3175, which most probably is an NO donor (Kankaanranta et al., 1996). The
GEA 3268 and GEA 5145 were originally chosen for the present study on the basis of results
concerning their potency in relaxation of guinea pig and rat bronchi when compared to their
derivatives of GEA 3162 and GEA 3175 (Paakkari et al., 1995; Vaali et al., 1996). It has been
suggested by Karup et al., (1994) that the enzymatic degradation of the sulfonamide moiety has
to take place before NO is released.
Inorganic NO donors. SNP (sodium nitroprusside, sodium pentacyanonitrosyl ferrate) had been
used to treat hypertensive crisis for nearly a century before the mechanism of action of NO was
discovered. Together with other commonly used anti-ischemic drugs like glyceryl trinitrate, amyl
nitrite and isosorbide dinitrate, it has the disadvantage of consuming organic reduced thiols. The
lack of reduced thiols has been implicated in tolerance (Needleman et al., 1973; Flaherty, 1989).
SNP is an inorganic complex, in which Fe2+ atom is surrounded by 4 cyanides, has a covalent
binding to NO, and forms an ion bond to one Na+. When the compound becomes decomposed,
cyanides are released and this may induce toxicity in long term clinical use. SNP releases NO
intracellularly (Hogg et al., 1992; Lipton et al., 1993) which can lead to problems in the
estimation of NO delivery. Though many possible forms of reactive NO derivatives have been
discussed (Feelisch, and Stamler, 1996), it is somewhat be surprising that in vitro SNP-induced
relaxation in guinea pig tracheal preparation has been reported to be induced completely via
cyclic GMP production (Hwang et al., 1998).
S-nitrosothiols (thionitrates, RSNO). S-nitroso-N-acetylpenicillamine (SNAP) is one of the most
commonly used NO donors in experimental research since the mid 1990’s. In physiological
solutions many nitrosothiols rapidly decompose to yield NO. The disadvantage of nitrosothiols is
that their half life can vary from seconds to hours even at a pH of 7.4, and this is dependent on
the buffer used. In physiological buffers, many of the RSNOs become decomposed rapidly to
yield disulfide and NO (Feelisch, and Stamler, 1996).
Sydnonimines. SIN-1 is the active metabolite of the antianginal prodrug molsidomine (N-
ethoxycarbonyl-3-morpholinosydnonimine), these two compounds are sydnonimines that are also
mesoionic heterocycles. Molsidomine as such cannot be used in in vitro experiments because
liver metabolism would be needed to turn it into its active form. SIN-1 is a potent vasorelaxant
and an antiplatelet agent causing spontaneous, extracellular release of NO (Hogg et al., 1992;
Lipton et al., 1993). SIN-1 can activate sGC independently of thiol groups. SIN-1 can rapidly and
non-enzymatically hydrolyze into SIN-1A when there are traces of oxygen present, it donates NO
and spontaneously turns into NO-deficient SIN-1C (Feelisch, and Stamler, 1996). Concentration-
dependently SIN-1C prevents human neutrophil degranulation and can reduce [Ca2+]i increase, a
property which is common to SIN-1 (Kankaanranta et al., 1997). SIN-1 has been shown to
release NO, ONOO- and O2- (Feelisch, 1991a).
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3. AIMS OF THE STUDY
The relaxation of different NO donating compounds; the β-agonist, salbutamol; and bradykinin;
in tracheal and bronchial airway preparations of different animals, were studied in smooth muscle
in vitro contracted with metacholine, histamine, or KCl. The roles of different K+ channels in
airway smooth muscle relaxation were estimated. The combination of NO donor and β-agonist in
the relaxation was studied.
More specifically, the aims were:
I To compare the relaxing effects of two novel experimental NO donors, GEA 3268 and
GEA 5145; with traditionally used NO donors, SNP and SIN-1; and with a β2-agonist,
salbutamol. The difference in vascular or bronchial tissues was evaluated by comparing the
relaxation potencies and efficacies in rat bronchial and mesentery artery preparations.
II To evaluate the involvement of the most important K+ channels in the guinea pig tracheal
relaxation. The roles of the selective sGC inhibitor, ODQ, and selective K+ channels blockers
were studied in the relaxation response induced by structurally different NO donors.
III To compare the relaxing mechanisms of three different relaxants: prostaglandin E2 and
NO -inducer bradykinin, the KATP channel opener lemakalim, and the classical NO donor SNP, in
the relaxation of mouse trachea. The involvement of different K+ channels in the relaxation of
these compounds was evaluated.
IV To study the possible interaction of the β-agonist and an NO donor. The effects of the β-
agonist, NO, and NO donor-induced relaxation are known to be mediated through the KCa
channels. Therefore, the possible interactions, i.e. not involving KCa channels were studied in
guinea pig trachea to evaluate whether alternative mechanism(s) also exist.
V To study the effect of non-selective phosphodiesterase inhibition and to measure cyclic
nucleotides concentrations in relation to relaxation to try to resolve the mechanism of the
interaction.
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4. MATERIALS AND METHODS
4.1. Experimental animals
BALB/c mice (8-12 weeks) of either sex, and male Wistar rats (9 weeks, 250-350 g) bred in the
Institute of Biomedicine, University of Helsinki were used. English shorthaired tricolored guinea-
pigs (350-450 g) of either sex bred in the Public Institute of Health, Helsinki, were used in I and
II studies. English shorthaired 9-11 month old (900-1200 g) tricolored male guinea-pigs bred by
Harlan, (HsdIf:TB, Winkerlmann GmbH, London, England), were used in IV study; and for
study V outbred Dunkin-Hartley male guinea-pigs (280-400 g, Mol:DUHA, Møllegaard,
Denmark), were kindly provided by Orion Pharma (Espoo, Finland).
The mice were kept in groups of 3-5 animals in Macrol Type III cage. The guinea pigs were kept
in groups of 2-3, and the rats in groups of 5-6 animals, on bedding from Tapwei, (Kaavi, Finland)
in standardized Macrol Type IV cages. The animals in the Institute of Biomedicine were housed
in conventional conditions at 22-24 ± 1°C, in light cycle of 12:12, controlled ventilation (change
of the air 10 times in an hour). The guinea pigs in Orion (study V) were housed in a barrier
animal room, 20±1°C, light cycle of 14:10. After arrival from the producer, guinea pigs were
given at least a week adaptation period before experimental use.
4.2. Tissue preparations
Mice were given 0.25 ml of pentobarbital sodium (60 mg kg-1 intraperitoneally). Guinea pigs (I-
IV) were anaesthetized with (75 mg kg-1 intraperitoneally) of pentobarbital sodium and
decapitated like the rats. Guinea pigs (V) were given a blow to the head and then decapitated.
Epitheliums of the preparations were kept intact. The preparations were excised immediately
into Krebs-Ringer solution which was prepared in ultrapure water of the following composition
(mM): NaCl 119, NaHCO3 25, glucose 11.1, CaCl2 x H2O 1.6, KCl 4.7, KH2PO4 1.2, MgSO4 x
7H2O 1.2, pH 7.4.
Rat mesenteric arteries were cut from the same animals as the bronchi and prepared and studied
as above. Both endothelium intact and denuded samples of arteries were prepared. The
endothelium was removed by gently rubbing the intimate surface.
4.3. Measurements of smooth muscle relaxation response and experimental procedure
Tracheal pieces (2-3 mm wide rings) were cut and mounted in an 10- or 8-ml organ chamber
containing the Krebs-Ringer buffer and aerated with a mixture of 96% O2 + 4% CO2 during the
experiments. The initial load, including the spontaneous tension for guinea pig and rat tracheas,
was set at 2.5g. (Not at 1.5g as erroneously has been written in studies I, II and IV.) The tracheas
of mice were equilibrated under an optimal resting tension of 0.4 g. The preparations were
allowed to stabilize for at least 40 min to reach their basal tone before any contracting agent was
added. Between the contractions, the preparations were washed every 15 min with Krebs-Ringer
buffer. The tension changes were recorded with Grass force displacement transducers and
amplifiers (FT03, Grass Medical Instruments, Quincy, MA, USA). The tone of the mice tracheal
smooth muscle (study III) was measured with the computerized complete bath systems using IT1-
25 transducers (EMKA Technologies, Paris, France).
35
Submaximal concentration of the contracting agents, metacholine (1 µM), histamine (1 µM) and
KCl (40 mM) were chosen on the basis of our previous studies. The 40-mM KCl used for
inducing contraction was prepared so that Na+ was replaced by K+, to produce a K+-rich
isoosmolar modification of the Krebs-Ringer buffer.
The rat arterial preparations were contracted with 1 µM noradrenaline and the presence or
absence of endothelium was tested with 1 µM ACh. Only after this, were the relaxing effects of
the NO donors studied in cumulative doses in 1 µM noradrenaline contraction.
In metacholine- or KCl-induced contraction an incubation time of 15 mins was enough to achieve
a stable contraction (I-III). However, in studies IV and V the incubation time was at least 35 mins
before relaxant drugs were added in order to reach maximum contraction with the contracting
agent.
Each concentration of relaxing drugs was allowed to take its effect for 6-8 min (studies I, II and
IV) or 10 min (study V) before the next concentration was administered. The whole study II
was carried out in the presence of indomethacin (3.3 µM), phentolamine (10 µM), propranolol
(1 µM), and NG-nitro-L-arginine (100 µM). Indomethacin was present throughout in order to
prevent the fading of neural response due to endogenous prostaglandin production.
Phentolamine, propranolol, and NG-nitro-L-arginine were added to inhibit α- and β-adrenergic
responses and the endogenous NO synthesis, respectively.
After the metacholine-induced contraction reached a plateau (study III), concentration-response
curves to bradykinin (0.01-1 µM) were obtained in a non-cumulative manner in order to avoid
the development of tachyphylaxis to bradykinin.
In studies IV and V after the first concentration of the cumulative drug (drug A), the modifying
drug (drug B) or its vehicle was added, then drug A was added cumulatively. The concentration
of drug B that would affect the relaxation only slightly was chosen.
In study IV the first contracting agent was always metacholine, and if this contraction was
relaxed with drug A, the next contraction (also metacholine-induced) was relaxed with drugs A
+ B. In every experiment, this procedure was carried out in half of the organ baths, the order of
the relaxing drugs was reversed with the other half, i.e. drug A + drug B in the first contraction,
drug A alone for the next contraction. All experiments were carried out for the same length of
time. When the first two contractions were obtained with metacholine, the next two were
obtained with KCl.
The pretreatment of ODQ, IBMX as well as the different K+ channel inhibitors or their vehicles
were added 10 min after metacholine administration. The pretreatment time was 20 min.
4.4. Preparation of tissue samples for cyclic nucleotide measurements
Trachea pieces were studied under similar conditions as above, but because the samples were
needed to be released from their hooks and put very quickly to liquid nitrogen, no initial
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mechanical load of 2.5 g as presented in the experiments with relaxation responses could be
used. However, metacholine induced contraction lasted for 30 min, and IBMX or its vehicle
were incubated for 20 min before salbutamol or / and SNP were added. Samples of 0.5, 1, 3, 6,
10, 30 or 60 min time points were taken, and the pieces were released from stainless steel hooks
and immediately frozen into liquid nitrogen. There was only one concentration of the relaxant
drugs (10 nM salbutamol, 0.33 µM SNP or the combination of these) that was added to the
organ baths before the sample was taken.
4.5. Cyclic nucleotide extraction and RIA measurements
The supernatants were acidified with HCl (25 mM final concentration) and extracted in room
temperature 5 times with 2 volumes of diethylether (water saturated) and lyophilized. Acetylated
cyclic GMP was determined with radioimmunoassay (RIA) according to Axelsson et al. (1988).
The cyclic GMP measurements were performed with [125I ]-cyclic GMP and in-house prepared
polyclonal rabbit antibody that cross-reacted less than 0.001 % with related compounds
(Lähteenmäki et al., 1998). Acetylated cyclic AMP was assayed by a commercial [125I ]-RIA-kit.
4.6. Protein measurements from tissue samples
The precipitation of the tissue homogenates was used for determination of proteins. The
precipitations were dissolved in 1 ml of 1 M NaOH +37°C overnight and assayed according to
Lowry et al. (1951) using 540 nm filters and microtitre well plate spectrometer (Labsystems,
Helsinki, Finland). Bovine serum albumin was used as a standard protein.
4.7. Nitrite and nitrate measurements
Krebs-Ringer buffer samples of NO2- and NO2- + NO3-, were collected in identical conditions (I)
at 37°C, and with 96% O2 + 4% CO2, but without tissue samples. Time points of 0, 5, 10, 15, 30,
60 min were used. The concentration of the NO donors used was 10 µM in order to detect
generated nitrite. The detection limit of the assay was 0.5 µM. NaNO2 diluted in water was used
for the calibration and produced linearly NO2- in the concentration range of 0 - 20 µM. The assay
for NOx was carried out according to Moshage et al. (1995) and Schmidt et al. (1992).
4.8. Calculation of synergy effects
Synergistic effects for drug A and drug B can be defined according to Berenbaum (1989), by
the following formula:
da/Da + db/Db < 1 synergy effect
da/Da + db/Db = 1 zero interaction
where da and db are the concentrations of drugs A and B used in combination and Da and Db are
their single concentrations which were isoeffective with the combination (da + db) at any
specified level of effect.
When drug A is added in cumulatively increased concentrations and the interacting drug B is
37
added in a single concentration, then, according to Pöch and Holzmann (1980), the theoretical
interaction can be calculated for each concentration of A in the presence of B from the respective
effects of A (EA) and B (EB) minus the combined effect of A and B (EA x EB):
EA+B = EA + EB - (EA x EB)
when E can be expressed as a fraction of the maximum effect (1.0). Using this equation and the
data for experimentally obtained relaxation for drugs A and B, the theoretical curves for
relaxation could be calculated with a spreadsheet. When the experimental curve for drugs A and
B shows greater potency than that of the theoretical interaction curve, the combination of drugs
has a positive synergy.
4.9. Compounds used in the study
Drugs from the following sources were used: GEA 3268, GEA 5145 and SIN-1 were synthesized
by A/S GEA, Farmaceutisk Fabrik (Hvidovre, Denmark). 4-AP, acetyl-β-methylcholine chloride,
acetylcholine chloride, apamin, bradykinin, bovine gamma globulin’s Cohn fraction II and III,
bovine serum albumin, ChTX, IbTX, indomethacin, noradrenaline ([-]-arterenol, bitartrate salt),
phentolamine hydrochloride, propranolol hydrochloride, SNAP, sulphanilamide, and unlabelled
cyclic GMP came from Sigma Chemicals (St. Louis, MO, USA). Pentobarbital sodium came
from Danisco Ingredients (Grinsted, Denmark), histamine acid phosphate from BDH LTD
(Poole, England), N-naphthylethylenediamine and the reagents for the Krebs-Ringer buffer came
from Riedel-de Haën (Seelze, Germany) and were prepared in ultrapure water of Millipore
(Bedford, MA, USA). Nitrate reductase (EC 1.6.6.2; Aspergillus species), NADPH, FAD, rabbit
muscle lactate dehydrogenase, and sodium pyruvate came from Boehringer-Mannheim
(Mannheim, Germany). NG-nitro-L-arginine and ODQ came from Alexis (Läufelfingen,
Switzerland). SNP was from Hoffmann-La Roche (Basel, Switzerland), diethylether from Lab-
Scan (Dublin, Ireland), sodium acetate and Folin-Ciocalteau’s phenol reagent were from Merck
(Darmstadt, Germany). [125I ]-cyclic GMP and cyclic AMP RIA -kit were prepared by Amersham
International (Little Chalfont, Buckinghamshire, England). Lemakalim (BRL 38227) was a gift
from SmithKline Beecham Pharmaceuticals (Surrey, UK), salbutamol from Leiras LTD (Turku,
Finland); glibenclamide and glipizide were from Orion Pharma (Espoo, Finland). IBMX was
kindly provided by Dr. Eeva Moilanen (Medical School, University of Tampere, Finland).
4.10. Determination of EC50, EC30, and statistics
An in-house prepared program (kindly provided by Mr. Arvi Salo, Tampere, Finland) was used to
determine the effective concentration (EC) of relaxant drug to produce 30 or 50 percent
relaxation. EC50 or EC30 values were determined using linear regression analysis applied to the
linear portion of each concentration-response curve.
The data are presented as mean ± S.E.M. of the indicated number of experiments. Analysis of
variance (ANOVA / MANOVA) was from the program Statistica, released 4.5. 1993 (Statsoft,
Inc. Tulsa OK, USA), followed by the Newman-Keuls test for multiple comparisons.
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4.11. Ethics
The procedures of studies I - IV were approved by the Animal Experimentation Committee of the
Institute of Biomedicine, University of Helsinki, Finland. The procedure of the study V was
approved by the Animal Experimentation Committee of Orion Pharma, Espoo, Finland.
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5. RESULTS
5.1. Relaxation of NO donors and β2-agonist in vitro in bronchial and arterial smooth
muscle
In guinea pig bronchi, the different NO donors, GEA 3268, GEA 5145, SNP and SIN-1, were less
potent relaxants than the β2-agonist, salbutamol (I). Salbutamol was most potent independent of
the contracting agent, metacholine, histamine, or KCl. When the efficacies of these drugs were
compared, salbutamol was the most efficient against metacholine contraction, equally efficient as
both GEA compounds against KCl contraction, and only somewhat less efficient when compared
to GEA compounds and SNP in histamine contraction. The novel GEA compounds were both
more potent and efficient than the old NO donors SNP and SIN-1.
In rat bronchi, all of these NO donors were more potent against metacholine than against KCl
contractions. In efficacy only SIN-1 was less efficient than salbutamol. In mesentery arteries of
rat, the denudation of endothelium did not significantly affect the relaxation of NO donors. When
all the compounds were compared in rat bronchial and arterial preparations, only salbutamol had
clear airway selectivity.
SIN-1 in both animal preparations was the least potent and efficient bronchorelaxant and in
arteries of rat it was the weakest vasorelaxant in potency and efficacy. However, SIN-1 generated
more NO2- and NO3- than the other NO donors studied, suggesting that the concentration of NO2-
and NO3- is not proportional to the relaxation potency and efficacy.
5.2. Effect of potassium channel inhibition in relaxation of structurally different NO donors
in guinea pig trachea
In guinea pig trachea, the relaxation induced by the NO donors GEA 3268, GEA 5145, SIN-1 and
SNAP could be concentration dependently inhibited with the GS inhibitor, ODQ (II). Therefore,
the relaxation was, at least partly, induced by the sGC stimulation, and thus, can be proposed to
be induced by production of cyclic GMP.
The selective inhibitor of the KCa channels, IbTX, concentration-dependently inhibited the
relaxing effects of these NO donors. Only the relaxation of SIN-1 against metacholine
contraction could not be inhibited by ChTX. In the presence of all the different NO donors, IbTX
inhibited the NO donor-induced relaxation response against metacholine contraction better than
ChTX. At high KCl contraction both SIN-1 and SNAP were concentration-dependently and
significantly (p<0.01) inhibited by IbTX, but GEA 3268 and GEA 5145 were less (p<0.05), and
this was not concentration-dependently true for GEA 5145. ChTX did not affect the relaxations
of GEA compounds against KCl contraction and had less effect with SIN-1 and SNAP.
Glibenclamide, the KATP sensitive inhibitor, and 4-AP, the KV channel inhibitor, did not affect the
relaxations of these NO donors.
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5.3. Relaxation induced by bradykinin, sodium nitroprusside, and lemakalim in mouse
trachea
The relaxations induced by SNP or bradykinin were not affected by the KV channel inhibitor 4-
AP; the SKCa inhibitor, apamin; the KCa inhibitors ChTX, IbTX; or the KATP inhibitors
glibenclamide and glipizide (III). Only the relaxant effects of lemakalim were inhibited with the
KATP channel inhibitors glibenclamide and glipizide.
5.4. Synergistic effect between the β2-agonist and NO donors in guinea pig trachea
It was shown that a combination of a nanomolar concentration of the β2-agonist, salbutamol, and
micromolar concentrations of NO donors, SNP and SIN-1, caused a synergistic relaxation in
metacholine contracted guinea pig tracheal smooth muscle (IV). When the contracting agent was
KCl, the results differed: no synergistic effect could be found.
Threshold levels of the modifying drugs concentration inducing the syngergistic effect were
identified. When the cumulative concentration-response curve of salbutamol was modified with
0.1 µM SNP or 0.33 µM SIN-1 no synergistic effect could be found. However, when the
concentrations of these drugs was increased to 0.33 µM and 1 µM, respectively, then synergy
was found.
With metacholine contraction, when the cumulative concentration-response curve of SNP was
modified by 0.1 nM salbutamol, no synergy was found, but increasing the concentration of the
modifying drug to 1 nM produced a synergistic effect that was very close to the theoretical
synergy effect. The same was not true when the cumulative concentration-response curve of SIN-
1 was modified with salbutamol (0.1 nM or 1 nM).
5.5. Role of the KCa channels and inhibition of phosphodiesterases in the synergistic
relaxation of β2-agonist and NO donor in guinea pig trachea
The role of the KCa channels was evaluated by using high concentration of the selective KCa
channel inhibitor, IbTX, and comparing the relaxations of single drugs with that of their
combination (V). Under the conditions used, IbTX inhibited approximately half of the effect of
salbutamol, SNP, or their combination.
The nonselective phosphodiesterase inhibitor, IBMX, at the highest concentration that could be
used without effect on the contraction level (1 µM), did not modify the cumulative relaxation of
salbutamol, SNP, or their combination.
5.6. Relaxation response as a function of time
When the effect of the combination of salbutamol (0.1 nM) and SNP (0.33 µM), in the first
concentration of drugs was studied in a cumulative relaxation response, the relaxation effect
reached its plateau by 10 min, but the most potent relaxation could be seen up to 3 min. The
relaxation responses in the absence or presence of IBMX did not differ from each other,
suggesting that inhibition of phosphodiesterases had no effect on relaxation as a function of time.
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5.7. Concentrations of cyclic nucleotides as a function of time
The concentrations of the cyclic nucleotides, cyclic GMP and cyclic AMP were measured with a
single concentration of the drugs and their combination, as a function of time, either in the
presence or in the absence of 1 µM IBMX. Low and high concentrations of salbutamol were
used, 0.1 nM or 1 µM respectively. SNP was studied in concentrations of 0.33 µM or 10 µM. The
combination of drugs was studied only at low concentrations (0.1 nM salbutamol together with
0.33 µM SNP).
Pretreatment with IBMX increased the cyclic GMP but not the cyclic AMP levels in control
samples before the relaxing drugs were added. In the presence of IBMX, however, there was a
consistent decrease in cyclic GMP levels caused by salbutamol (0.1 nM), SNP (0.33 µM), or their
combination, between the time points of 0.5 to 1 mins in all three cases studied. This did not
correlate with the contracting levels in the case of salbutamol alone. The only increase in cyclic
GMP was observed with the combination of drugs at 3 mins. The only significant change from
the baseline in cyclic AMP was seen with SNP at 6 min.
In the absence of IBMX there was no difference in the cyclic GMP levels in any of the cases.
During 1-3 minutes, the concentrations of cyclic AMP did not decrease or increase significantly
in the presence or absence of IBMX. In the absence of IBMX, the increase in cyclic AMP was
not significant with salbutamol and with the combination, but it appeared in both cases at the
same time-points.
With high concentrations of drugs, salbutamol (1 µM) or SNP (10 µM), at the same time points,
pretreatment with IBMX were shown to increase the concentrations of both cyclic nucleotides. In
the presence of IBMX, there was a significant decrease in cyclic GMP concentration at the 0.5
min time point caused by salbutamol (1 µM) but the cyclic AMP concentrations increased up to 3
mins. Also, the presence of IBMX caused a decrease in cyclic GMP levels with SNP (10 µM) at
1 mins.
When all the studied cases are considered, it seemed that there was no correlation between the
levels of cyclic nucleotides and the relaxation response achieved.
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6. DISCUSSION
The experimental NO donors GEA 3268 and GEA 5145 were synthesized to obtain compounds
that would slowly and non-enzymatically release low concentrations of NO and that would not
consume reduced thiol groups. Previous studies with several different derivatives of GEA
compounds have demonstrated their potency to relax guinea pig tracheal preparations in the
organ bath as well as their ability to inhibit bronchoconstriction in anaesthetized guinea pigs
Corell et al., (1994). NO donors have been proposed to have anti-asthmatic effects and potential
use in chronic obstructive pulmonary disease Alving et al., (1993a) and Dinh-Xuan et al., (1993).
NO has also been shown to attenuate interleukin 2-induced lung injury in Sprague-Dawley rats
(Bouchier-Hayes et al., 1997), and a very low concentrations of inhaled NO (0.5 - 10 ppm) have
been clinically demonstrated to reduce pulmonary artery pressure and to improve gas exchange
(Troncy et al., 1997). NOS inhibitors applied to the airway surface lead to increased plasma
exudation (Erjefält, 1994) and NO donors increase in vitro mucus secretion in humans (Nagaki et
al., 1995). These form the background for the idea to use NO donors to treat asthma, although at
the time of study there were many publications where NO had been shown to induce
inflammation, but there were no reports of any beneficial, anti-inflammatory effects.
Although NO levels have been shown to be increased in the exhaled air of asthmatics, quite
recently, RSNOs have been shown to be decreased in the airway lining fluid of asthmatic
children (Gaston et al., 1998). Also, in the same study, children with severe asthma had low
airway thiol concentrations, leading to an increased degradation of RSNO. However, patients
with mild forms of asthma have increased airway thiol concentrations (Lewis et al., 1993).
Therefore, it is to be expected that in the near future research in airway pharmacology will try to
resolve this problem and whether NO donors will find any place in the treatment will depend on
these results.
In addition, the possible positive or negative synergistic effects of the combination of NO donor
and β2-agonists were studied.
6.1. Comparison of the potencies and efficacies of the different NO donors and selection of
the airway preparation
Different NO donors, GEA 3268, GEA 5145, SNP and SIN-1, were always less potent relaxants
in guinea pig bronchi than the β2-agonist, salbutamol (I). The novel GEA compounds were
generally more potent bronchorelaxants than SNP or SIN-1 in both guinea pig and rat
preparations. NO donors are less potent than salbutamol also in human bronchi in vitro (Corompt
et al., 1998). The potency and efficacy does not correlate with the ability of these compounds to
evoke NOx production.
The amount of β-receptors in the rat lung (Rugg et al., 1978) is 3-fold lower than that of the
guinea-pig (Barnes 1980) and 75 % of the rat adrenoreceptors are β2-subtype (Rugg et al 1978).
The rat lungs do not have an adrenergic nerve supply to their bronchial muscle (Bivin et al 1979).
Therefore, it could be suggested that other endogenous mediators must be responsible for rat
proximal airways relaxation and compensate for the absence of the β-receptors. NO donors could
be potent bronchorelaxants if NO in vivo is important in rat airway relaxation. However,
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relaxation of guinea pig bronchus in vitro resembles better human bronchus in is sensitivity to β2-
agonists and in the moderate potency of NO donors, and therefore was chosen for use in the
present series of experiments.
Although there was no significant difference in the relaxation of rat mesentery artery preparations
in the presence or absence of endothelium, it could be suggested from the results that
endothelium tends to prevent the exogenous NO or its derivatives from reaching the underlying
smooth muscle cells. It can be also concluded that no clear airway selectivity of the novel drugs
GEA 3268 or GEA 5145 could be found. Salbutamol is the only drug that is clearly more airway
selective on the basis of these experiments.
6.2. Evaluation of NO and cyclic GMP production of the different NO donors
NO production was evaluated by analyzing NO2- and NO3- production from the NO donors in the
Krebs buffer (I), and by measurement of relaxation in the presence and absence of a sGC
inhibitor, ODQ (II). The production of NO2- and NO3- was very weak from GEA 3268 and from
SNP, but Karup et al., (1994) has shown by three different methods - modified Werringloer’s
technique of co-oxidation of oxyhemoglobin to methemoglobin, NO release by headspace gas
analysis - that GEA 3268 does release NO. In the present study, relaxation of GEA 3268 was
inhibited concentration-dependently by ODQ in metacholine and in KCl contractions. GEA 3268
and GEA 5145 are derivatives of GEA 3162 which has been shown to be an NO donor; and of
GEA 3175 which most probably is an NO donor (Kankaanranta et al., 1996). It is also hard to
draw any conclusions or the extent of NO production on the basis of NOx production.
There are many publications describing the production of peroxynitrite (ONOO-), which is
generated by the reaction of O2- with NO. SIN-1 extracellularly releases a bolus dose of NO, and
O2- rapidly reacts with NO to form ONOO- (Augusto et al., 1994; Feelisch, 1991b; Hogg et al.,
1992). ONOO- can also induce coronary vasorelaxation in dogs (Liu et al., 1994). We could show
production of NO2- and NO3- to be potently induced when SIN-1 was used. This confirms the
results of Korbut et al., (1995) where high NO production from SIN-1 was evaluated by
measuring co-oxidation of oxyhemoglobin to methemoglobin when NO was oxidized to NO2-
and NO3-.
There is increasing number of different NO-related compounds (table 4) that have longer lasting
activities of relaxation than NO itself. RSNOs can induce bronchodilation of isolated ventilated
guinea pig lung (Bannenberg et al., 1995), relaxation of human bronchial smooth muscle in vitro
(Gaston et al., 1994, 1993) and different RSNOs are in vitro approximately 100 times less potent
than salbutamol but 75 to 35 times more potent than theophylline in guinea pig trachea (Jansen et
al., 1992).
Our results with ODQ, which is a very specific sGC inhibitor, suggest that most of the relaxing
effect in guinea pig tracheal preparation has been due to cyclic GMP production, as the relaxation
induced by SIN-1 could be concentration-dependently and totally inhibited by ODQ.
Unfortunately, SNP was not evaluated when the relaxation in the presence of ODQ was studied
(II). However, Hwang et al., (1998) studied cumulative, concentration-dependent relaxation of
SNP in guinea pig trachea, and showed that 10µM ODQ almost completely abolished relaxation
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responses induced by a maximum concentration (30µM SNP). In metacholine contracted
preparations, the relaxations of GEA 3268 and GEA 5145 were significantly inhibited by ODQ
but there may be other mechanisms that can cause relaxation. GEA 3268 and GEA 5145 induced
relaxations unaffected by ODQ when they were present at over micromolar concentrations. In the
same concentration range, these drugs were not inhibited by 100 nM IbTX, suggesting that these
drugs have other mechanisms of relaxation besides NO donation or formation of NO derivatives
in guinea pig airway preparations.
Because of the problems with these NO donors, the possible other effects of the GEA compounds
(i.e. in addition to NO donation), forced us to select two candidates for the following studies.
SNP and SIN-1 were chosen to be used to study the interaction of β-agonist and NO. However,
we also used bradykinin to evoke endogenous production of NO and compared bradykinin with
SNP in the study of mouse tracheal relaxation.
6.3. Relaxation mediated by the KCa channels
The effects of all four different NO donors, GEA 3268, GEA 5145, SIN-1 and SNAP to inhibit
metacholine contraction were prevented with selective blockade (IbTX) of the KCa channels (III).
With the metacholine contraction, the relaxation induced by SIN-1 could not be inhibited by
ChTX. This toxin can also inhibit other K+ channels (Hermann and Erxleben, 1989; Vázquez et
al., 1990).
The results with different NO donors against KCl contraction in the presence and absence of
IbTX suggest that some of the NO donors also have other relaxing effects in addition to
activation of the KCa channels. In KCl contracted preparations both SIN-1 and SNAP were
significantly inhibited by IbTX but the effects of GEA 3268 and GEA 5145 were less inhibited,
and GEA 5145 was not inhibited at all in a concentration-dependent manner. The result is
complicated because when there is high concentration of KCl, inhibition of K+ channels does not
necessary affect relaxation (Hamaguchi et al., 1992). Therefore, the results of the KCa channel
inhibition in the presence of high Ke are difficult to interpret.
In brief, KCa channel inhibitors reduced NO donor-induced tracheal relaxation.
6.4. The reliability of the results from the KATP channels
In guinea pig trachea, pretreatment with glibenclamide did not modify the relaxation by the NO
donors used (II). There are several reasons why one must be cautious before drawing conclusions
on the role of KATP channels from published in vitro studies.
The KATP channels are only very weakly voltage dependent and are activated when intracellular
ATP concentration is lowered (Noma 1983). In in vitro experiments glucose (9.5-11 mM) or
dextrose (5 mM) concentrations are kept relatively high and constant, which should result in a
high intracellular ATP concentration. This in turn, closes the KATP channels, and thus it could be
possible that adding a KATP blocker does not have any effect on the relaxing property of these NO
donors in guinea pig tracheal smooth muscle, and has possibly no effect in most of the other
smooth muscle preparations. Examples of such is study in guinea pig trachea, main pulmonary
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artery, its left branch, carotid artery, and aorta (Bialecki and Stinson-Fisher, 1995); as well as by
Isaac et al., (1996) where guinea pig trachea was studied. Several other studies examining porcine
(Hayabuchi et al., 1998) and guinea pig (Eckman et al., 1998) coronary arteries could not show
any effect on relaxation when glibenclamide was used. It should be kept in mind that in such
experiments lemakalim, the opener of the KATP channels, has often been used as a control drug
when the effects of closure of the KATP channels by glibenclamide have been studied. The
channel opener might have direct and strong effects on the Po of the KATP channels, but the other
studied relaxants might have indirect, or weaker effects.
The KATP channel openers force their channels to stay open, but the presence of energy source
could mean that KATP channels would be 85% closed, for example. Glibenclamide may induce,
for example, 95% closure of the channels. This difference may then be too small to affect the
results significantly, especially, when the conductivity of the channels is lower, and the amount
of the KATP channels is much smaller (1,000 / cell) than that of all the other K+ channels together
(only KCa channels and the KV channels are both 10,000 / cell), (Edwards and Weston, 1994).
However, in many such studies the interpretation has been that the KATP channels have no effect
on the relaxation.
Therefore, we have studied in vitro relaxation induced by GEA 3268 and GEA 5145 in the
absence of glucose in guinea pig trachea (unpublished results). It would be expected that in the
absence of an energy source, the preparations could not produce a stable contraction during the
experiment. This was not the case, and the results still clearly showed that the relaxations induced
by these compounds are not mediated through the KATP channels. It must be remembered,
however, that there is no biophysical evidence in the literature showing that KATP channels exist
in guinea pig trachea.
Very recently Shyng and Nichols (1998), and Baukrowitz et al., (1998) showed in patch clamp
experiments that much of the previously published information concerning ATP sensitivity of
KATP channels was incorrect. The inhibition constant (Ki) for ATP in intact cells is 100 higher
than in clamp studies of excised cells. The presence of phosphatidylinositol-4,5-bisphosphate
(PIP2) and phosphatidylinositol-4-phosphate (PIP) lowered the Ki close to the value of intact
cells. This finding could explain the different results for ATP sensitivity of various tissues and
studies (Cameron and Baghdady, 1994; Tricarico et al., 1997). The interpretation is that the
results of the KATP channels and in patch clamp (representing non-intact cells) are possibly very
remote from the situation of relaxation in organ bath (representing intact cells).
6.5. The results from the KV channel inhibition
For the same reasons as discussed above concerning the KATP channels, it could be argued that
the results of KV channels in organ bath experiments should be evaluated cautiously. Since these
channels have no known agonists, there is no other pharmacological way to study them but to use
4-AP that can bind to the channels and induce blockade. When the Po of KV channels is highest in
depolarization, depolarization by contracting agent and blocking the channels with 4-AP induces
closure of the channels. In the presence or absence of 4-AP there was no difference in the
relaxation curves of any of the NO donors studied, suggesting that these channels would not be
affected by NO donors. No interfering substance (i.e. such as high glucose concentration in the
case of KATP channels) is known to exist.
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There is evidence that 4-AP has muscarinic effects, but these may not interfere with our findings
in guinea pig trachea: Isaac et al. (1996) noted that 4-AP did not affect guinea pig tracheal
preparations in metacholine- nor in KCl-induced contractions. In our study, when metacholine or
KCl were used as the contracting agents, 4-AP was added after the contraction had been attained.
6.6. Relaxation of mouse trachea by bradykinin, lemakalim and SNP
The presence or absence of the subtype selective K+ channel inhibitors, relaxations were not
affected by either a cyclic AMP-producing agent, bradykinin; or a cyclic GMP-producing agent,
SNP, in mice trachea (III); i.e. these compounds do not mediate their relaxation through the KCa-,
SKCa-, KATP-, or KV channels in BALB/c. Therefore it could be suggested that K+ channels may
be contain different combinations of subunits in mouse trachea, and would not be inhibited under
the conditions used here.
It is of interest that the maximum relaxation responses achieved in mice have not reached the
potency and efficacy which can be obtained in rats or guinea pigs. The maximum relaxations
against 1 µM metacholine contraction by 10 µM bradykinin and by 100 µM SNP were only about
45% in our study. Heuven-Nolsen et al., (1997), achieved 70% relaxation with 0.33 µM
bradykinin and 1 µM capsaicin, but the contracting agent was only 0.1 µM carbachol. The results
from our study and that of Heuven-Nolsen et al., (1997) are difficult to compare, e.g. it is
possible that by increasing the concentration of the contracting agent may cause a degree of
functional antagonism of the relaxation as has been reported in canine trachea (Torphy et al.,
1983) and in guinea pig trachea (Kume and Kotlikoff, 1991), see Fig. 5.
Later it was shown that bradykinin does not induce relaxation through the NO pathway in
BALB/c mouse tracheal smooth muscle (Heuven-Nolsen et al., 1997; Li et al., 1998b).
Bradykinin-induced relaxation is mediated through B2 receptors and has been suggested to
produce prostaglandins, possibly prostaglandin E2, that can activate AC to produce cyclic AMP.
We showed that the relaxation caused by lemakalim could be inhibited by glibenclamide,
suggesting that there is pharmacological evidence of KATP channels present in the BALB/c mouse
trachea. The problems concerning the KATP channels described above prevent us from making
any firm conclusions on the role of these channels in this preparation.
We have also later shown that the relaxation induced by SNP in mouse trachea can be inhibited
by the selective sGC inhibitor, ODQ (Li et al., 1998b). Taken together, it can be suggested that
there is production of cyclic GMP in mouse trachea, but that relaxation is not mediated through
the KCa channels. In guinea pig, human, and porcine airway smooth muscle, SNP has been shown
to be involved in opening of the KCa channels (Hamaguchi et al., 1992; Jones et al., 1990;
Yamakage et al., 1996).
The clear importance of the KCa channels in the relaxation of smooth muscle in many kinds of
tissues and in all species - but their insignificant effect in the relaxation of mouse trachea -
suggests that there is a very different balance of airway tone regulation between mouse and other
species. Therefore, mouse seems to be a rather poor model for the experimental asthma research
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when the airway relaxation is to be studied, and this should be noted when genetically
manipulated mice are used in the screening of new drugs.
6.7. Synergistic relaxation effect of salbutamol and NO donors
The results (V) from young barrier-housed (2.5 to 3.5 months old) Dunkin-Hartley guinea pigs,
and those of our previous studies (IV) in which old English shorthaired tricolored male guinea
pigs (9 to 11 months old) housed in conventional conditions were used, showed a similar
synergistic effect between the β2-agonist salbutamol and an NO donor SNP in tracheal
preparation in vitro. Thus the interaction is reproducible - and importantly - age- and breed-
independent.
When the KCa channel inhibitor, IbTX was present, the results of the single drugs together with
their combination suggested that the role of the KCa channels could account for half of the
relaxation of metacholine contracted trachea (V).
When the contracting agent was KCl, the combination of the β2-agonist and the NO donor did not
induce any synergistic relaxation (IV). This could have been due to inactivation of the KCa
channels by depolarization of the plasma membrane induced by high Ke concentration. The
results with the selective KCa channel inhibitor, IbTX are in accordance with the following
theory: IbTX can inhibit the relaxation only partially. A high K+ concentration opens other ion
channels and extracellular Ca2+ leaks in, leading to a decrease in Po of the KCa channels. If the
combination of drugs decreases [Ca2+]i, then in KCl contraction the combined effect is weaker
than the influence of Ca2+. Therefore, these results with KCl are in accordance with our results
with IbTX when the combination of drugs was evaluated.
6.8. Role of phosphodiesterase inhibition in the combination of a β-agonist and an NO
donor
IBMX could not modify the relaxation effects of salbutamol or SNP (V), as would be expected
with the combination of phosphodiesterase inhibition and the increase of cyclic nucleotides. The
concentration of IBMX used (1 µM) can be regarded as low when compared to several studies on
the effects of cyclic nucleotides (100 µM). However, higher concentrations of salbutamol (1 µM)
and SNP (10 µM) in the presence of IBMX increased the cyclic nucleotide levels significantly.
Also, the pretreatment of IBMX alone without any relaxants increased the cyclic GMP levels.
However, there was a decrease in cyclic GMP concentrations at the 1-3 min time points with
salbutamol (0.1 nM), SNP (0.33µM), or their combination, although the relaxation of the
combination attained its maximum independently of whether IBMX was present or absent.
Phosphodiesterase inhibition has been studied as a treatment of asthma for decades. It is well
known that phosphodiesterase inhibition with low concentrations of non-selective or with the
novel more selective drugs does not relax the guinea pig tracheal preparation. Commonly
millimolar concentrations of phosphodiesterase inhibitors are needed in vitro to induce
relaxation, although these drugs can induce anti-inflammatory effects at much lower
concentrations in vivo (Morley, 1994). When the anti-inflammatory effects are studied in cell
culture or other in vitro methods, the concentrations needed are again at the millimolar levels. On
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this basis it would be unexpected that the combination of salbutamol and SNP in the very low
concentrations studied would inhibit phosphodiesterases sufficiently to achieve in vitro
relaxation. Therefore, we propose that phosphodiesterase inhibition is not the reason for the
synergistic effect.
6.9. Fluctuation of cyclic nucleotides levels as a function of time and relaxation
Our results with very low concentrations of β2-agonist and the NO donor revealed that the
relaxation appears to be independent of cyclic nucleotide concentration (V). This does not mean
that the entire relaxation is induced without participation of cyclic nucleotides, but part of the
relaxation effect of the β-agonist or NO can directly activate KCa channels as shown by Kume et
al., (1989) and by Bolotina et al., (1994), respectively. Also the relaxant effects of openers of
KATP channels, BRL-34915 and pinacidil, are independent of cyclic nucleotide changes and are
thought to be totally dependent on membrane potential (Gillespie and Sheng, 1988). In our
experiments, however, the there was a very poor correlation between the cyclic nucleotide
concentration and the relaxation response achieved.
Cyclic GMP could be used up by intracellular proteins. It is possible that in earlier studies this
kind of decrease was not found because the studies were done mostly in high concentrations of
cyclic nucleotides, and therefore, any slight decrease was hidden by this strong increase, i.e. the
intracellular system could not consume all of the cyclic GMP pool. We suggest that the
combination of drugs exceeds a threshold level of activation.
The fluctuations in cyclic nucleotides concentration is difficult to interpret as there are many
levels at which cyclic GMP and cyclic AMP could take place. Possibly the most important ones
are when the different phosphodiesterase isoenzymes become active and when the cell is
stimulated extracellularly. The best example of fluctuation is the inhibition of phosphodiesterase
type III in guinea pig trachea. An increase of cyclic GMP may inhibit phosphodiesterase type III
which leads to decreased catabolism of cyclic AMP, which then leads to activation of PKA. PKA
in turn activates type V, which degradades cyclic GMP (Pyne et al., 1996). This kind of positive
or negative feedback can be one reason for the fluctuation of the cyclic nucleotide levels as a
function of time. Therefore, the system is not easy to comprehend with the methods used in our
study, and would require extensive experimentation with assays of type-specific
phosphodiesterase activation measurements together with measurements of cyclic nucleotide
concentration.
In bovine coronary arteries Kukovetz et al., (1979) showed by using four different nitro
compounds that there was a very good correlation (r=0.98) between the increase in cyclic GMP
and the maximum relaxation at 20 mins, but the increase in cyclic GMP exceeded the relaxation
response between 1 to 5 mins with all the studied compounds. No decrease in cyclic GMP was
reported, which could be explained by different tissues. It is possible that cyclic nucleotides were
compartmentalized during the first minutes of relaxation, but after a longer incubation time the
distribution becomes steady in the preparations.
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6.10. The possible mechanism of relaxation other than through activation of the KCa
channels
There is evidence in the literature for inhibition of Ca2+ influx in response to cyclic GMP
increase, and cyclic AMP can promote activation of Ca2+ influx.
β-agonists have also been shown to activate L-type Ca2+ channels in cells isolated from trachea
(Welling et al. 1992), which may suggest that β-agonists mediate their relaxing effects in part
also through intracellular calcium flux. In bovine tracheal smooth muscle, isoprenaline or
forskolin elevate [Ca2+]i, although both drugs inhibit the initial and plateau response of [Ca2+]i in
response to carbachol challenge (Felbel et al., 1988).
Felbel et al. (1988) have shown with freshly isolated bovine tracheal smooth muscle cells that
IBMX and 8-Br-cyclic GMP decreased [Ca2+]i, and by activating PKG, prevented the carbachol-
induced elevation in [Ca2+]i. Fischmeister and Hartzell (1987) have studied the effect of cyclic
AMP and cyclic GMP on Ca2+ currents in single frog ventricle cells with a whole-cell patch-
clamp. Isoprenaline and cyclic AMP increased the Ca2+ current, but in the presence of cyclic
GMP, the current was inhibited. Later, a catalytically active fragment of PKG (which could not
be modulated by cyclic GMP) was shown (Mery et al., 1991) to exert a strong inhibitory effect on
the Ca2+ current in the presence of cyclic AMP. Guinea pig acinar cells treated with SNP and
inhibition of GS (Pandol and Schoeffield-Payne, 1990) have also been shown to affect the Ca2+
current. In rat cerebral arteries an increase in local Ca2+ concentration, can cause activation of the
KCa channels such as that obtained with cyclic AMP-elevating (forskolin), and cyclic GMP-
elevating (SNP and nicorandil) compounds (Nelson et al. 1995). Small pulses - the so-called Ca2+
sparks - close to the channel activate the channel (Nelson et al. 1995). These Ca2+ sparks do not,
however, increase the total intracellular Ca2+ concentration sufficient to induce contraction
(Porter et al. 1998).
In rat aortic smooth muscle cells, NO has been shown to inhibit intracellular Ca2+-release induced
by noradrenaline, but not by caffeine (Ji et al., 1998). Cyclic GMP may also affect Ca2+ release
through inhibition of phosphoinositol 4,5-bisphosphate (PIP2) degradation (Godfraind, 1986). In
agreement with this, NO has been shown in porcine tracheal smooth muscle to inhibit
intracellular Ca2+-release (Kannan et al., 1997).
In the study of the mechanism(s) of combination of an NO donor and β-agonist it would be
reasonable to study the involvement of changes in [Ca2+]i concentration. There are also several
possible mechanisms through which the receptor-G-protein-phospholipase C pathway could
regulate cyclic GMP, but these lie beyond the scope of the present study. It is possible that
inhibition of the Ca2+ current is at least one of the contributing mechanisms which in addition to
activation of KCa channels, could account for the synergistic relaxation seen with those two drugs.
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7. SUMMARY AND CONCLUSIONS
NO donors are weaker in potency and efficacy in relaxing guinea pig than rat bronchial smooth
muscle, but salbutamol is most potent at relaxing guinea pig bronchial tissue and weakest in the
corresponding tissue in rat. This suggests that in studies with different NO donors, the guinea pig
bronchial preparation would be an appropriate model to mimic human bronchial relaxation. No
airway smooth muscle selectivity of the studied NO donors could be seen.
The ability of structurally different NO donors to relax guinea pig trachea was prevented by
selective inhibition of sGC by ODQ; and by inhibiting the KCa channels with their selective
inhibitors, IbTX and ChTX. The role of other K+ channels could not be shown to be important in
the relaxation induced by the NO donors.
In BALB/c mouse trachea bradykinin- and SNP-induced relaxations could not be modified with
the selective K+ channel inhibitors. None of the following drugs could modify those relaxations;
KCa channel inhibitors, IbTX or ChTX; SKCa channel inhibitor, apamin; KATP channel inhibitors,
glibenclamide or glipizide; KV channel inhibitor, 4-AP. Lemakalim, an opener of the KATP
channels, could concentration-dependently relax the trachea. The relaxations were inhibited by
glibenclamide and glipizide, suggesting that these channels exist in mouse trachea. However, in
several other animal species, K+ channels - especially the KCa channels - play an important role in
smooth muscle relaxation.
The relaxation obtained with nanomolar concentrations of the β2-agonist, salbutamol, could be
potentiated by micromolar concentrations of an NO donor. A positive synergistic effect could be
shown against metacholine contraction, but not against KCl contraction. However, since an
important effect of the NO donors studied is to activate the KCa channels, then this effect should
not be apparent when there is a high KCl concentration.
The non-selective phosphodiesterase inhibitor, IBMX, at the highest concentration used, still did
not modify the relaxation curves of the β-agonist, salbutamol, or the dose response curve to the
NO donor, SNP. However, very low concentration of drugs did produce the synergistic effect, but
the concentrations of cyclic nucleotides did not correlate with the measured relaxation responses.
In the presence of IBMX, there was no significant difference in cyclic AMP concentrations, but a
major change was in the concentration of cyclic GMP during the first minutes. At the same time
when there was a strong relaxation with the combination of these drugs, though there was no or
only minor relaxation in the preparations when either drug was given alone.
Clementi and Meldolesi (1997) have proposed that the current drugs, i.e. NO donors and
inhibitors of NOS, GC and PKG are not sufficiently efficacious in modulating the signalling
effect of NO pathway to be of benefit in treating chronic diseases such as hypertension, tumor,
and infections. Similarly, it could be argued that the cyclic AMP pathways could also be
strengthened. In this study, this hypothesis was confirmed: the relaxation produced by the most
potent bronchodilators currently available, i.e. β2-agonists, could be potentiated by addition of an
NO releasing compound to the system.
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